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Measles is a highly contagious, vaccine-preventable illness caused by the measles 
virus. Previously unexposed humans and non-human primates are susceptible to disease. 
Upon infection, virus travels to lymphoid tissue and then to multiple organs resulting in a 
systemic infection. Clinically, the onset of rash occurs 10-14 days after infection and 
coincides with the appearance of the adaptive immune response. Infection within the host 
is characterized by a robust virus-specific immune response leading to eventual recovery 
and establishment of life-long immunity. Paradoxically, measles virus infections are also 
associated with a transient period of immune suppression leading to increased 
susceptibility to secondary infections.  Recent strides have been made toward global 
measles control through the use of mass vaccination campaigns, however various 
logistical and financial barriers have hindered sustained vaccine efforts. In addition there 
has been a recent resurgence of measles in many industrialized nations, mainly due to 
objections to vaccination based on complacency or various philosophical and religious 
beliefs.   The World Health Organization (WHO) estimated that approximately 134,200 








Measles virus (MeV) is an enveloped, single-stranded, negative-sense RNA virus. 
MeV is a member of the morbillivirus genus and Paramyxoviridae family [1]. The 
measles genome is approximately 16 kb and encodes for six structural and two non-
structural proteins [1] (Figure 1-1).  The hemaglutinin (H) protein is a type II 
transmembrane glycoprotein that is an important determinant of morbillivirus tropism 
[2]. H binds to cellular receptors and interacts with the fusion (F) protein to mediate 
fusion of the viral envelope with the host cell membrane for viral entry. Fusion occurs via 
a conformational change in both proteins triggered by H binding to cell-surface receptors 
[3]. The matrix (M) protein interacts with the cytoplasmic tail of H and F glycoproteins, 
modulates the targeting and fusogenic capacity of envelope glycoproteins, and directs 
virus release from the apical surface of epithelial cells [4].  The nucleocapsid (N) protein 
is typically the most abundant protein and is required to encapsidate viral RNA for 
replication and transcription. The N-terminal domain of this protein is required for virus 
assembly and packaging [5, 6]. The phosphoprotein (P) and the large (L) protein function 
in association with each other for the virus’ RNA-dependent RNA-polymerase [7]. The P 
gene encodes two additional MeV non-structural proteins C and V, which are important 
modulators of the host IFN response [8].  
Currently there are three known cellular receptors for MeV: CD46 [9, 10], CD150 (or 
SLAM) [11], and nectin-4 [12]. CD46 is a human complement regulatory protein 
expressed on all nucleated cells and preferentially on the apical surface of polarized cells. 
There are four isoforms in humans, all of which MeV can utilize as receptors. In addition, 
monkeys have a CD46 homolog that can be utilized by MeV [13]. Signaling lymphocyte 
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activation molecule (SLAM or CD150) is a glycoprotein expressed on cells of the 
immune system: immature thymocytes, activated T and B-lymphocytes, activated 
monocytes, and mature dendritic cells. Most MeV vaccine strains can utilize CD46 
efficiently, while wild-type (WT) strains do not. In contrast, both WT and vaccine strains 
can use SLAM as a receptor however the affinity and efficiency differ. The distributions 
of CD46 and SLAM in tissues don’t account for MeV replication in epithelial cells (in 
vivo or vitro). Poliovirus receptor-like 4 (nectin 4) is an adherens junction protein of the 
immunoglobulin superfamily and has been identified as the receptor located on 
basolateral side of epithelial cells [12].  
 
1.2 Epidemiology 
Measles is a highly contagious respiratory disease that caused millions of deaths 
annually before the introduction of an effective vaccine in the1960’s. Due to its high 
infectivity, sustained vaccine efforts are important for interruption of the transmission 
cycle. The basic reproductive number (R0), or the mean number of secondary cases that 
arise if an infectious individual is introduced into a completely susceptible population, is 
estimated to be 12 to 18 for measles [14]. Based on this high R0, the level of population 
immunity (herd immunity) necessary to interrupt measles transmission is between 93 to 
95%.  
The dynamics of measles outbreaks in populations have been very well characterized. 
When endemic, measles incidence typically displays a temporal pattern characterized by 
annual seasonal epidemics superimposed on longer 2-5 year epidemic cycles [15]. 
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Seasonal fluctuations in measles transmission are generally correlated with fluctuations in 
population density [16].   
Humans are the only reservoir for measles virus. There is also no evidence of latent 
or persistent infections that confer long-term contagiousness. Thus, measles eradication is 
considered feasible. While significant progress has been made in reducing global measles 
incidence, the requirement for high levels of herd immunity makes control efforts more 
difficult. In addition, there are a number of logistical and financial challenges that need to 
be met for eventual measles eradication to be achieved.  
 
1.3 Pathogenesis and Pathology 
Measles is transmitted from person to person via respiratory droplets or aerosols. 
After the introduction of virus into the respiratory tract, alveolar macrophages and 
dendritic cells become infected and transport virus to draining lymphoid tissues. Once 
transported to lymphoid tissue the immune response is initiated, virus is amplified, and 
then spreads systemically to infect multiple organs [17-19].  Infected immune cells (B 
cells, CD4+ and CD8+ T cells, monocytes) are primarily responsible for viral 
dissemination to various tissues including lymph node, spleen, liver, lungs, and skin [20, 
21]. There is an incubation period of 10-14 days and a 2-3 day prodrome of fever, cough, 
and conjunctivitis followed by the appearance of the prototypical maculopapular rash 
(Figure 1-1). Individuals are most infectious from 5 days before through 5 days after the 
onset of rash [22]. In addition, the onset of rash coincides with the appearance of adaptive 
immune responses and initiation of virus clearance[22]. While infectious virus is 
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typically cleared by 2-3 weeks post-infection, the clearance of viral RNA is much slower 
[23].  
In immunocompetent individuals, infection typically results in a robust virus specific 
immune response, which allows them to eventually recover. However, the transient 
period of immune suppression cause by measles can result in susceptibility to 
opportunistic infections, which result in most measles associated morbidities and 
mortalities. In rare cases, measles can establish persistent infection in the CNS leading to 
the development of  measles inclusion body encephalitis (MIBE) or subacute sclerosing 
panencephalitis (SSPE), which may occur months to years after acute MeV infection 
[24]. Lastly, recovery from infection typically results in the acquisition of life-long 
immunity to reinfection.  
 
1.4 Host Immune Responses to MeV 
The immune responses to MeV are important for virus clearance, recovery from 
infection, and protection from re-infection and are also responsible for several of the 
clinical manifestations of disease. The roles of various components of the immune 
response in recovery have been mainly determined from documented outcomes of natural 
measles infection of patients with deficiencies in immunologic function. However, our 
more detailed understanding of the importance of various immune components have 
come from experimental infection of macaques, which allow for longitudinal studies of 
virus-specific immune responses and depletion of specific components of the immune 
system. In general, deficits in antibody production permit recovery, while deficits in 
cellular immune responses may lead to slowed clearance and progressive disease. 
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Innate Immune Response 
The innate immune system provides an immediate first line of defense against 
infections. In short, this immune response is triggered in a cell intrinsic manner when 
pattern recognition receptors (PRRs) within the infected cell sense the virus and trigger 
downstream signaling cascades that activate immunity. The activation of innate immune 
responses can not only act directly to suppress viral replication and dissemination to other 
cells, but is also critical for programming subsequent adaptive immune responses. Many 
viruses have evolved ways to inactivate various innate immune signaling factors in order 
to escape immune surveillance, thus, determining the role and importance of specific 
components of the innate response during infection can be difficult.  
In vitro studies have shown that MeV RNA or proteins interact with PRRs and can 
activate NFkB and IRF-3 signaling pathways in a strain-dependent and cell-type specific 
manner. Epithelial cells show activation of NFκB and AP-1 (activator protein-1) and 
increased production of the chemokine CXCL8 (IL-8) in response to MeV infection [25, 
26]. However, the NFκB pathway and tumor necrosis factor-α (TNF-α) production are 
suppressed in acute and persistently infected monocytes, potentially as a result of the up-
regulation of the ubiquitin-modifying enzyme TNFAIP3 (A20), a negative regulator of 
NFκB [26-28]. 
Some inflammatory cytokines and chemokines are induced in vivo during measles. 
Levels of TNFα, IL-6, IL-8, IL-1β and IL-18 are increased in plasma of children during 
measles with elevated levels of TNFα and IL-1β being associated with in-hospital 
mortality [29-32]. IL-1β mRNA and protein are increased in MeV-infected monocyte-
derived cells and in PBMCs isolated from patients after rash onset [27, 28, 33]. 
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Additional in vitro studies suggest that MeV infection leads to NLRP3 inflammasome 
activation, resulting in caspase-1 mediated maturation of IL-1β [34]. The production of 
inflammatory chemokines is important for cell homing to infected tissues.  Levels of 
chemokines CCL2, CCL4, CCL13, CXCL8 and CXCL10, are elevated in children with 
measles, and levels were higher in children who died in-hospital compared to those who 
survived to discharge [32].  
Type I IFN (IFNα/ IFNβ) and Type III IFN (IFNλ, IL28a, IL-28b, IL-29) can be 
induced as part of the innate immune response to viral infection. IFN induction typically 
occurs when signaling pathways are activated after virus recognition by PRRs such as 
toll-like receptors and RNA helicases. Both Type I and III IFNs activate the JAK-STAT 
signaling pathway and lead to the induction of IFN-stimulated genes, which encode for 
various proteins that can inhibit viral replication. In vitro and in vivo studies suggest that 
in the absence of defective interfering RNAs, neither WT nor vaccine strains of MeV 
efficiently induce Type I or III IFN [35]. The RNA helicases, RIG-I and MDA-5, are 
cytosolic PRRs that sense viral RNA in infected cells, interact with a common adaptor 
MAVS (also known as VISA/Cardif/IPS-1) and ultimately activate signaling pathways 
that lead to Type I IFN induction (Figure 1-3).  
The MeV C and V proteins, encoded within the P gene, appear to be the main viral 
proteins that prevent the induction of IFN pathways [36]. The MeV V protein has been 
shown to block IFN induction by directly binding to MDA-5 (Figure 1-2) [36]. 
Subsequent studies demonstrated that the V protein is able to inhibit MDA-5 activation 
by a forming a complex with PP1α/γ thereby preventing MDA-5 dephosphorylation 
(Figure 1-2) [37, 38]. Additionally, MeV can also target PP1 in dendritic cells (DCs) by 
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interacting with DC-SIGN.  MeV binding to DC-SIGN signals the activation of Raf-1, 
which leads to the inhibition of PP1 and suppresses RIG-I and MDA-5 activation (Figure 
1-2) [39]. Alternatively, the V protein of MeV can prevent IRF-7 mediated activation of 
type I IFNs by binding IKKα (Figure 1-3) [36].  The MeV C protein has a more indirect 
effect on type I IFN induction. The C protein has been shown to be a negative regulator 
of viral RNA synthesis and thus acts to inhibit IFN induction via blocking the production 
of PAMPs [8].  
 
Humoral Immune Response 
 Measles-specific humoral immune responses are important for protection and may 
contribute to recovery from infection. Antibodies to measles virus are sufficient for 
protection because infants are protected by passively acquired maternal antibodies, and 
administration of anti-measles immune globulin partially protects children from measles 
after exposure [40]. Humoral immunity seems to play a very limited role in viral 
clearance as transient depletion of CD20+ B cells in macaques does not affect clearance 
of infectious virus [41]. However, in MeV-infected individuals, antibody-dependent 
cellular cytotoxicity correlates temporally with clearance of cell-associated virus from the 
blood [42].  
Antibody production is dependent on the activation and differentiation of B cells. 
B cells become activated upon the binding of antigen to the B cell receptor (BCR) via 
interaction with activated helper T cells. Upon activation, B cells proliferate and can 
differentiate into antibody secreting cells (short- or long-lived) or memory B cells. MeV-
specific antibodies are first detectable at the onset of rash. Measles-specific IgM appears 
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within 72 hours after rash onset and is maintained for 28 days, while IgG responses are 
generated shortly after and are maintained for decades. The IgG isotype is initially IgG2 
and IgG3 followed by a switch to predominantly IgG1 and IgG4 in the memory phase 
[43]. IgA, IgM, and IgG antibodies to MeV can not only be detected in serum but also in 
nasopharyngeal secretions and saliva, thus providing the opportunity to use noninvasive 
methods for determining immune status.  
MeV-specific antibodies are produced to most MeV proteins but appear first and 
most abundantly to N, then H and F, respectively. MeV-specific neutralizing antibodies 
correlate with protection and play a key role in preventing subsequent MeV infections. 
The majority of neutralizing antibodies are specific for the H glycoprotein, however F-
specific antibodies also display some neutralizing activity [44-46]. Neutralization is 
generally measured by plaque reduction of the Edmonston strain of MeV on CD46-
expressing Vero cells.  
 
Cellular Immune Response 
Several lines of evidence suggest that cellular immunity may be important for 
measles virus control and clearance. Children with agammaglobulinemia recover from 
measles while those with impaired cellular immunity often develop progressive infection 
of the lungs and CNS [47, 48]. During the acute phase of disease, the appearance of 
cellular immune responses tends to coincide with the onset of the rash (Figure 1-4). 
Biopsy of the rash shows infiltration of CD4+ and CD8+ T cells in areas of MeV-infected 
epithelial cells, demonstrating that the rash is a manifestation of the cellular immune 
response [49]. Studies involving experimental infection of macaques has allowed for 
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longitudinal analysis of the MeV-specific cellular immune response however, the relative 
contributions of specific subsets of T cells to protection and immunity are not completely 
understood.  
The two major subsets of T cells are CD4+ and CD8+ T cells. During measles, both 
CD4+ and CD8+ T cells are activated and expanded. CD8+ T cells, also known as 
cytotoxic T cells, function to eliminate virally infected cells. CD8+ T cells are considered 
to be most important for the control and clearance of MeV. Depletion of CD8+ T cells in 
macaques resulted in more severe symptoms and prolonged viremia compared to control 
macaques [49]. Additionally, ex vivo stimulation of PBMCs with MeV-specific peptides 
have shown that CD8+ T cells are expanded, have cytotoxic activity, and produce IFNγ 
demonstrating that effector memory is established during infection [50-54]. 
T-helper (CD4+) cells play a central role in immune protection and have various 
immune functions depending on the cytokines they produce. Upon encountering antigen 
in the context of MHC class II on the surface of antigen presenting cells, naïve CD4+ T 
cells become activated and can differentiate into different subsets: Th1, Th2, Th9, Th17, 
Th22, regulatory T cells (Tregs), and follicular helper T cells (Tfh). Th1 cells produce 
IFNγ, IL-2, and TNFα, and mediate immune responses against intracellular pathogens. 
Th2 cells produce IL-4, IL-5, IL-10, and IL-13 that are important for mediating host 
defenses to extracellular parasites and B cell proliferation. Treg cells play a critical role 
in maintaining self-tolerance as well as regulating immune responses via the production 
of IL-10 and TGFβ.  
 T-helper type 1 (Th1) responses tend to be predominant during the acute phase of 
measles predominantly producing IFNγ and IL-2, while the convalescent phase of 
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infection appears to be skewed towards T-helper type 2 (Th2) and regulatory T cell 
(Treg) responses associated with the production of IL-4, IL-10, and IL-13 [55-58] (Figure 
1-4). Early production of IFNγ may be important for controlling virus spread as it has 
been shown to suppress MeV replication in vitro in epithelial and endothelial cells [59] 
and in vivo in the brains of infected rodents [60, 61]. The shift to the production of type 2 
cytokines is likely to promote B cell proliferation and contribute to the continued 
production of antibody-secreting cells. Tregs are induced during measles, however their 
exact role in pathogenesis is still unknown. Detection of CD4+ CD25+ Tregs has been 
reported in humans and SLAM-expressing mice during measles virus infection [62, 63]. 
Furthermore, MeV-infected macaques have sustained upregulation of Foxp3, a Treg-
specific transcription factor, after clearance of infectious virus [23]. A role for Th17 and 
Tfh cells in measles has not yet been described.  
The humoral immune response is typically the primary focus when assessing vaccine 
efficacy and protection from measles, and most studies largely correlate serum antibodies 
with protection [64]. However, a few studies using both wild-type and vaccine strain 
measles viruses demonstrate that insufficient or impaired cellular immune responses may 
lead to delayed clearance of MeV RNA and progressive or even fatal infection [65]. 
These observations suggest that host immunity and MeV control and clearance are a 
complex orchestration between the cellular and humoral arms of the immune response.  
 
1.5 MeV-induced Immune Suppression 
 The paradox of measles is that the acute phase of infection is not only associated 
with immune activation and a robust virus-specific adaptive immune response that leads 
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to recovery and lifelong immunity, but also with profound immune suppression. The 
immunosuppressive effects of measles were first recognized in 1908 by von Pirquet who 
described the loss of delayed type hypersensitivity responses to tuberculin in MeV-
infected individuals [66, 67]. While the exact mechanism of MeV-induced immune 
suppression is not completely understood, several factors have been proposed to 
contribute to this phenomenon:  (1) lymphopenia, (2) functional impairment of immune 
cells, (3) imbalance of cytokine production, and most recently (4) depletion of CD150+ 
memory lymphocytes [68, 69].  
The acute phase of MeV infection is associated with decreased numbers of T cells 
and B cells in circulation and lymphoid tissue [70-72]. This loss of mature lymphocytes 
due to infection is likely to contribute to lymphopenia. The MeV receptor, CD150, is 
expressed at high levels by activated CD45ROhigh memory T-lymphocytes and a subset of 
B-lymphocytes that are preferentially depleted during infection [18, 73, 74]. Altered 
trafficking and increased susceptibility to cell death are also likely to contribute to a 
decrease in lymphocytes [70, 75, 76]. T cell numbers return to normal after 10 days once 
clinical symptoms have subsided [31, 70, 72]. Therefore, it is likely that lymphocyte 
depletion in the periphery plays only a minimal role in prolonged measles-induced 
immune suppression.  
Various subsets of DCs are susceptible to MeV infection. Infection of DCs in 
vitro results in the loss of the ability of these cells to stimulate the proliferation of naïve 
CD4+ T cells in a mixed leukocyte reaction [77]. CD40-activated DCs show enhanced 
replication of MeV. Furthermore, enhancing replication of MeV during DC-T cell 
interaction leads to a decrease in the production of IL-12, decreased capacity for T cell 
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proliferation, and massive cell death [78]. Therefore, it is possible that MeV-induced 
immune suppression may result from impaired DC function and antigen presentation. 
However, in vivo, strong MeV-specific immune responses are developed resulting in 
rapid clearance of infectious virus and establishment of life-long immunity.  
Alteration of the immune response during the acute phase of measles versus the 
recovery phase provides some insight into mechanisms that may contribute to immune 
suppression. During acute measles, there is a strong Th1 response associated with a rise 
in IFNγ and IL-2. After resolution of the rash, levels of IL-4, IL-10 and IL-13 are 
elevated suggesting that Th2 and regulatory T cells are preferentially activated during the 
recovery phase [57, 79, 80]. IL-12 is produced by antigen presenting cells and promotes 
Th1 development and production of IFNγ. Therefore, it has been suggested that the lack 
of IL-12 production during measles recovery may contribute to the Th2 skewing of the 
cytokine profile and immunosuppression [81, 82]. However, vaccination of monkeys 
with a recombinant MeV expressing IL-12 resulted in alteration of the Th2 bias of the 
immune response, had no effect on lymphopenia, and did not improve in vitro 
lymphoproliferative responses [83] Therefore, if IL-12 does play a role in MeV-induced 
immune suppression it may not be a key player. Th2 cytokine predominance may be 
important for the development and maturation of the humoral immune response; 
however, it may also function in preventing the induction of Th1 responses that may be 
required to combat new infections.  
Observations from rhesus and cynomolgus macaques infected with recombinant 
MeV strains expressing enhanced GFP (EGFP) have provided an additional in vivo tool 
for time-course analysis of infection and development of an alternative model to explain 
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measles immune suppression [84, 85]. Data from these studies showed that MeV targets 
lymphoid tissues, preferentially infects memory T cells, and causes lymphocyte depletion 
and exhaustion in lymphoid tissues during the acute phase of infection. Based on these 
observations, it has been proposed that preferential infection and subsequent immune-
mediated depletion of CD150+ memory T cells results in temporary immunological 
amnesia [20, 69]. Additionally, the short duration of lymphopenia followed by prolonged 
immune suppression may be due the expansion of new MeV-specific and bystander 
lymphocytes that replace depleted memory T cell populations and eventual restoration of 
immunological memory. Together this model would explain why measles-associated 
immune suppression extends beyond the period of lymphopenia with increased 
susceptibility to secondary infections during this time.    
 
1.6 Measles Studies in the Macaque Model 
Measles is generally recognized as a human disease. At the beginning of the 
twentieth century, it was demonstrated that MeV could be transmitted from humans to 
macaques. Subsequently, numerous studies demonstrated that macaques experimentally 
infected with wild-type strains of MeV mimic many of the clinical, pathological, and 
immunological patterns seen in humans [86-88].  As a result, much of our more detailed 
understanding of measles pathogenesis, immune responses, and sites of virus replication 
come from studies in nonhuman primates (NHP).  
The two NHP species commonly used to study measles pathogenesis are rhesus 
macaques (Macaca mulatta) and cynomolgus macaques (Macaca fascicularis). However, 
clinical signs such as rash and conjunctivitis tend to be more prominent in rhesus 
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macaques [86, 87, 89]. Marmosets are highly susceptible to measles infection, but have 
not been studied extensively because unlike humans, they often develop disease that is 
fatal [90].  
Naturally acquired infection with WT strains of MeV tends to cause recognizable, 
clinical evidence of measles however, many laboratory strains of MeV often do not 
produce disease in primates. Infections with MeV isolated in cell culture demonstrated 
the importance of passage history as virus strains passaged in lymphoid cells retained 
pathogenicity in macaques, and passage in other cell lines often resulted in virus 
attenuation. B95a cells (EBV transformed marmoset B cell line), PBMCs from human 
cord blood, or COBLa cells (T cell line from cord blood) are ideal for the isolation of WT 
MeV from patient samples to retain its pathogenicity in macaques [87, 88, 91]. 
Alternatively, Bankamp et al. (2008) demonstrated that WT MeV isolated from Vero 
cells expressing CD150 (Vero/hSLAM) and not in unmodified Vero cells retained its 
pathogenicity in macaques and induced skin rash [92], thus, demonstrating that CD150 
expression of cells used for virus isolation is crucial and that cells do not have to be of 
lymphoid origin.  
Monkeys infected with Bilthoven WT strain of MeV develop Koplik’s spots, 
conjunctivitis, and maculopapular rash by 7-10 dpi. The rash may persist for up to 5 days. 
Chicago-1, Edmonston wild type, Moraten, STL-91, and LA-89 infection of monkeys 
typically do not result in clinical illness [87]. MeV infection induces strong specific 
humoral and cellular responses in macaques and recovery is accompanied by lifelong 
immunity. The macaque model has been crucial for studying the early events following 
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virus transmission, especially because in humans measles is typically not recognized 
before the onset of rash.  
 
1.7  Prevention and Control 
Measles resulted in millions of deaths before the introduction of an effective vaccine. 
The first attempt to vaccinate occurred in 1749 when the Scottish physician, Francis 
Home, inoculated individuals with blood taken from measles patients. In 1954, Enders 
and Peebles successfully isolated measles virus from a 13-year old measles patient, David 
Edmonston. The Edmonston strain of MeV was successfully propagated in human and 
monkey cells which led to the development of both inactivated and live-attenuated virus 
vaccines (Figure 1-5) [93]. The inactivated vaccine, licensed in 1963, only provided 
short-term protection and recipients who were re-infected often developed more severe 
disease described as atypical measles. However, further attenuation of the live-attenuated 
virus vaccine has led to the highly effective vaccines used worldwide today [94]. The 
Schwarz vaccine, which was licensed in 1965, is the standard vaccine in much of the 
world (Figure 1-5). Maurice Hilleman developed the Moraten strain, licensed in 1968, 
and it is the only vaccine administered in the United States (Figure 1-5) [95]. Despite the 
differences in passage history and attenuation methods used to develop the Schwartz and 
Moraten vaccine strains, they are identical in sequence [96].  
The recommended age for vaccination is typically between 9 to 15 months and varies 
regionally based on optimum age for seroconversion and the probability of acquiring 
measles before that age. Two doses of the measles vaccine are needed to provide 
sufficient population immunity to interrupt transmission [97]. The first dose is typically 
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administered through the primary health-care system at age 9 months in areas where 
measles remains prevalent and at 12-15 months in low-risk areas. Two strategies in place 
to administer the second dose are either through the primary health care system or mass 
vaccination campaigns. These immunization strategies have made remarkable progress in 
reducing measles incidence and mortality worldwide. However, there are still major 
logistical, financial, and political challenges that could hinder sustained vaccination 
































Figure 1-1. Measles virus. Schematic representation of the measles virion structure (A). 
Measles virus is an enveloped, negative strand RNA virus. The measles virus genome (B) 
is approximately 16kb and encodes for six structural proteins and two non-structural 














Figure 1-2. Measles virus suppresses activation of RLRs. In response to various RNA 
viral infections, PP1 dephosphorylates MDA-5 and RIG-I resulting in their activation and 
the production of type I and II interferons (IFNs). MeV can inhibit this antiviral response 
by targeting PP1. MeV inhibits PP1 activity in dendritic cels via its interaction with DC-
SIGN on the cel surface. MeV binding to DC-SIGN signals the activation of Raf-1, 
which facilitates the formation of a GADD34-PP1 holoenzyme, thereby inhibiting PP1 
phosphatase activity (1). Additionaly, MeV V protein blocks PP1 activity by directly 
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Figure 1-3. MeV can inhibit type I IFN production by TLR7 and TLR9. Activation 
of TLR7 and 9 results in the recruitment of MyD88, which in turn recruits a complex 
containing TRAF3, TRAF6, IRAK and leads to the activation of IKKα. IKKα 
phosphorylates IRF-7 resulting in its nuclear translocation and ultimately the production 
of type I IFNs. The V protein of MeV directly binds to IKKα preventing the 
phosphorylation of IRF-7 resulting in the inhibition of type I IFN production. Figure 
adapted from Nature Reviews Immunology [100]. 
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Figure 1-4. Pathogenesis of measles virus infection. Measles virus infection is initiated 
in the respiratory tract then spreads to multiple organs (A). Clinical symptoms begin 10 
to 12 days post-exposure and the appearance of rash begins with the clearance of 
infectous virus (B). The rash is a manifestation of the adaptive immune response. There is 
a robust virus-specific immune response during infection, including rapid expansion of T 
cels and prolonged production of IgG (C). Cytokine profiles include the predominant 
production of the type I cytokines, IL-2 and IFNγ, folowed by a switch to type I and 








Figure 1-5. Passage history of Edmonston vaccines. Several MeV vaccines were 
derived from a single clinical isolate called the Edmonston strain. Enders et al. 
developed the first MeV vaccine by serial passage of the virus isolate in human 
kidney cells. The virus was attenuated by subsequent passage in chicken embryos and 
chick fibroblast cells. Variations of the Enders approach have led to the development 




Virus clearance and the innate immune response during a primary 
wild-type measles infection 
2.1 ABSTRACT 
Measles remains a significant childhood disease. In most individuals, the immune 
response is able to successfully clear measles virus (MeV) infection and life-long 
immunity is established. However, infection is also associated with several weeks of 
immune suppression. As a result, most measles-associated deaths are attributed to 
secondary infections. Previous work has shown that viral RNA persists in PBMCs four to 
five times longer than infectious virus. The goal of our study was to further characterize 
the prolonged presence of viral RNA in multiple tissues and also in various immune cells 
using a rhesus macaque model. We found that viral RNA could be detected in the blood 
and lymph node months after infectious virus is cleared, and preferentially persists in B 
cells and monocytes.  
 The innate immune response to viral infection often includes induction of type I 
IFNs and production of antiviral proteins.  A number of in vitro and in vivo studies have 
shown that neither wild-type nor vaccine strains of MeV induce type I IFN. To gain more 
insight into MeV inhibition of type I IFN induction, we assessed levels of biologically 
active IFN by bioassay and used a PCR array to assess the differential expression of 
genes involved in type I IFN production. Our work confirms previous observations that 
type I IFN induction is inhibited by MeV infection and suggests that MeV modulates the 
activation of various pattern recognition receptors (PRRs) involved in the type I IFN 
pathway.  
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2.2  INTRODUCTION 
Measles virus is a member of the Paramyxoviridae family and has a negative-sense, 
single-stranded RNA genome measuring approximately 16 kb that encodes eight 
proteins. The hemagglutinin (H) and fusion (F) surface glycoproteins mediate virus 
fusion and entry. The matrix (M) protein lines the interior of the viral envelope. The 
nucleocapsid (N) protein is the first to be transcribed from the genome and is therefore, 
the most abundant of the viral proteins [1]. The genomic RNA is wrapped within the N 
protein and is packed within the envelope with the phosphoprotein (P) and large 
polymerase (L) protein attached [1, 102]. There are two non-structural proteins, C and V, 
encoded within the P gene that interact with cellular proteins and modulate host immune 
responses [103-105].  
Measles is an important cause of childhood morbidity and mortality. Measles results 
in systemic illness and is associated with persistent viral RNA and several weeks of 
immune suppression. Paradoxically, measles infection also induces robust virus-specific 
responses leading to the eventual viral clearance and the establishment of life-long 
immunity. Activation of the innate immune response is essential for the initial control of 
viral infections because it slows down replication before adaptive immunity becomes 
activated. Like many other viruses, measles has acquired various strategies to evade the 
host immune response including, modulation of IFN responses. 
 
Prolonged clearance of MeV RNA 
Measles is a systemic disease transmitted via the respiratory route. Epidemiological 
evidence suggests that persons with measles are infectious several days before and after 
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the onset of rash [106]. Clinical recovery occurs soon after the onset of rash at 10-14 days 
post-infection and coincides with the clearance of infectious virus from the blood. 
Despite the rapid clearance of infectious virus, MeV RNA persists in peripheral blood 
mononuclear cells (PBMCs), urine and nasopharyngeal secretions in naturally infected 
children for several months [107, 108]. Mechanisms of immune-mediated clearance of 
infectious virus and viral RNA from different types of cells are still unknown, but likely 
to vary and occur at different rates. However, T-cell primed macaques cleared viral RNA 
more rapidly than unimmunized animals after challenge with wild-type MeV [109].  In 
addition, MeV RNA can still be detected in HIV-infected children one-month after 
hospital discharge [107]. In monkeys, depletion of CD8+ T cells, but not B cells results 
in a higher and more prolonged viremia [49]. These data suggest that viral clearance is 
delayed when cellular immune responses are compromised. 
Subsequent studies in experimentally infected rhesus macaques characterized the 
dynamics of MeV RNA clearance from PBMCs [23]. These studies demonstrated that 
viral RNA clearance from the peripheral circulation occurs in three phases. After an 
initial peak in viral RNA at 7-10 days, there is a rapid decline coincident with the 
clearance of infectious virus (10-14 days), followed by a rebound phase with up to a 10-
fold increase in RNA levels (14-24 days) and then a slow decline to undetectable levels 
by 60 days post-infection [23]. However, viral RNA can still be detected in lymph nodes, 





Regulation of type I interferon production by measles 
 The type I interferon (IFN) family includes IFNα (13 subtypes in humans) and 
IFNβ. Almost all cells in the body can produce IFNα/β, and this usually occurs via the 
stimulation of pattern recognition receptors (PRRs) by microbial products. The RIG-I-
like receptors (RLR), retinoic acid-inducible gene (RIG-I) and melanoma differentiation-
associated gene (MDA-5) are the main cytosolic PRRs that sense viral RNA. Activation 
of RIG-I and MDA-5 result in a cascade of downstream signaling events, which lead to 
the induction of various transcription factors that activate the transcription of IFNα/β. In 
most cases, the transcription factors IFN-regulatory factor 3 (IRF3), IFN-regulatory 
factor 7 (IRF7), nuclear factor-κB (NF-κB), and activator protein 1 (AP-1) are the 
primary regulators of IFNα/β transcription. A number of paramyxoviruses, including 
measles virus, have the ability to regulate the production of type I IFN. The measles 
genome encodes for two non-structural proteins, C and V, within the P gene that interact 
with cellular proteins and antagonize type I IFN induction [103-105] 
 Measles virus has evolved multiple strategies to inhibit RLR sensing and 
activation. Recent studies suggest that measles virus inhibits type I IFN production by 
targeting PP1 phosphatases thereby preventing RIG-I and MDA-5 dephosphorylation and 
activation [37, 39] The MeV V protein blocks IFN induction by directly binding to 
MDA-5 [36] or by a forming a complex with PP1α/γ ultimately preventing MDA-5 and 
RIG-I dephosphorylation and activation (Chapter 1, Figure 1-2) [37, 38]. Additionally, 
MeV can target PP1 in dendritic cells (DCs) by interacting with DC-SIGN leading to the 
suppression of RIG-I and MDA-5 activation (Chapter 1, Figure 1-2) [39]  
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Alternatively, the V protein of MeV can prevent type I IFN induction by TLR7 and 
TLR9 by directly binding to IKKα or IRF-7 [36, 110, 111]. The MeV C protein has a 
more indirect effect on type I IFN induction. The C protein is a negative regulator of viral 
RNA synthesis and thus acts to inhibit IFN induction via blocking the production of 
PAMPs [8].  
The transcription factor, NFkB, is involved in the regulation and efficiency of IFNβ 
transcription along with the upregulation of a large number of genes that encode for 
proinflammatory cytokines, chemokines, cell survival genes, and antimicrobial proteins.  
In vitro studies have shown that MeV RNA or proteins interact with PRRs and can 
activate NFkB and IRF-3 signaling pathways in a strain-dependent and cell-type specific 
manner. Epithelial cells show activation of NFκB and AP-1 (activator protein-1), 
however their activation is suppressed in acute and persistently infected monocytes [25-
28]. Moreover, the V protein binds the NFκB subunit p65 (RelA) [104]. This interaction 
prevents NFκB nuclear translocation, thereby interfering with IFNβ transcription.  
 
Regulation of type I interferon signaling by measles virus 
 The measles virus V protein interferes with type I IFN signaling. IFNα and IFNβ 
signal through direct binding to the transmembrane cell surface receptors, IFNAR1 and 
IFNAR2. Ligation of IFNAR results in activation and recruitment of Janus kinase 1 
(JAK1) and tyrosine kinase 2 (TYK2). In the canonical pathway, activated JAK1 and 
TYK2 phosphorylate signal transducer and activator of transcription 1 (STAT1) and 
STAT2. Phosphorylation of this complex leads to its nuclear translocation and ultimately 
the induction of interferon-stimulated genes (ISGs).  Yeast two-hybrid screens and co-
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immunoprecipitation studies have shown that the measles virus V protein binds directly 
to STAT1 and JAK1 to block type I IFN signaling [112]. The V protein also prevents the 
phosphorylation of Tyk2 [112].  
 The magnitude of MeV RNA persistence in various tissues past 90 dpi have not 
yet been investigated, and the mechanism and consequences of persistence are not clear. 
Additionally, it is clear that the innate response to MeV does not involve the induction of 
type I IFN however, changes in the gene expression profile associated with type I IFN 
activation have not yet been described. Therefore, the overall goals of our study were 
two-fold. First, to determine the extent of MeV RNA persistence in multiple tissues and 
various subsets of immune cells through 6 months post-infection; and second, to assess 
type I IFN activity and alterations in the expression of genes associated with type I IFN 
activation and signaling during MeV infection. We hypothesize that a primary wild-type 
measles infection will be characterized by the prolonged presence of MeV RNA in 
PBMCs of the blood and lymph node with preferential persistence of viral RNA in B cell 
populations.  In addition, we expect that MeV infection will result in the inhibition of 
type I IFN activity along with a down-regulation of genes associated with type I IFN 
production and activation.  
  
2.3 MATERIALS AND METHODS 
Animals, infection and procedures 
Six 3-year-old male measles-naïve rhesus macaques (Macaca mulatta; 14Y, 17Y, 24Y, 
31Y, 46Y and 50Y) were obtained from the Johns Hopkins Primate Breeding Facility. 
Samples from a second group of rhesus macaques (46U, 55U, 67U, 40V, 43V, and 55V) 
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from a previous study were also used in the current study [23]. The Bilthoven strain of 
wild-type MeV (genotype C2; gift of Albert Osterhaus, Erasmus University, Rotterdam) 
was grown in phytohemagglutinin-stimulated human cord blood cells and assayed by 
plaque formation on Vero/hSLAM cells [113]. Following baseline measurements, 
monkeys were infected intratracheally with 104 plaque-forming units of MeV in 1 ml 
PBS. Upon development of a rash, group 1 monkeys received either two daily doses of 
vitamin A (100,000 units, Vitamin Angels, Santa Barbara, CA; 14Y, 24Y, 50Y) or 
placebo (17Y, 31Y, 46Y). No differences were observed between supplemented and non-
supplemented macaques, so data have been pooled. Macaque 24Y did not develop 
measles-specific antibodies so he was excluded from all data analysis, and will be 
discussed further in Chapter 5.  
Heparinized blood was collected from the femoral vein before infection and every 
3-14 days after infection for six months. PBMCs and plasma were isolated by whole 
blood gradient centrifugation on Lympholyte-Mammal (Cedarlane Labs). Inguinal lymph 
node biopsies were collected at days 71 and 154 post-infection. For all procedures, 
monkeys were sedated with 10-15 mg/kg ketamine intramuscularly.  All studies were 
performed in accordance with experimental protocols approved by the Johns Hopkins 
University Institutional Animal Care and Use Committee. 
 
Viremia 
Infectious MeV in blood was measured by co-cultivating serially diluted fresh 
PBMCs (105 to 100) with Vero/hSLAM cells in 48-well plates. Co-cultures were 
incubated for 5-6 days at 37°C, 5% CO2. Cytopathic effects in each well were assessed 
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and the 50% tissue culture infectious dose (TCID50) calculated.  Level of viremia is 
expressed as the logTCID50 per million PBMCs.  
 
RT-PCR 
To monitor MeV shedding from the respiratory tract, nasal secretions were collected 
from both nostrils with sterile cotton swabs and immersed in PBS. Samples were 
centrifuged to collect the cells and supernatant fluids for storage at -80°C. The RNeasy® 
Plus Micro Kit (Qiagen) was used to isolate RNA from the nasal cells. RNA was eluted 
in 30µl of RNase-free water and 10 ng or 10 µl were used for RT-PCR. Primers MV41 
and MV42 were used to amplify a 350 base pair N gene sequence (Table 2-1), and human 
β-actin RT-PCR primers (Agilent) were used as a control for RNA quality. PCR products 
were run on gels and read as positive or negative. 
 
MeV N Gene Expression – qRT-PCR 
MeV RNA in PBMCs and mononuclear cells isolated from the LN was quantified by 
qRT-PCR as previously described [23, 114]. Mononuclear cells isolated from the LN 
were first sorted using magnetic beads into CD3+, CD20+, and CD14+ populations. 
Briefly, total RNA was isolated from 2x106 PBMCs and the N gene was amplified 
(Applied Biosystems Prism 7700) using a one-step RT-PCR kit with TaqMan primers 
and probe (Table 2-1).  Controls included GAPDH amplification (Applied Biosystems) 
and RNA isolated from cultured PBMCs from MeV-naïve monkeys. Copy number was 
determined by construction of a standard curve from 101-108 copies of RNA synthesized 
by in vitro transcription from a plasmid encoding the Edmonston N gene.  The sensitivity 
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of the assay was 50-100 copies.  Data were normalized to the GAPDH control and 
expressed as [(copies of MeV N RNA)/(copies of GAPDH RNA)] x 5,000.  
 
MeV N Gene Expression – ddPCR 
Digital droplet PCR (ddPCR) was used to quantify MeV RNA in various subsets 
of immune cells. Isolated PBMCs were sorted using magnetic beads into CD3+, CD20+, 
and CD14+ populations. The RNeasy® Plus Micro Kit (Qiagen) was used to isolate RNA 
from sorted cells. RNA was eluted in RNase free water and 100 ng were used to make 
cDNA using the iScript™ Advanced cDNA synthesis kit (BioRad, Hercules, CA). A 20 
µl mixture of primers, probes, Bio-Rad 2X Supermix (no dUTP) and 5 µl of cDNA was 
prepared and emulsified with droplet generator oil (Bio-Rad, Hercules, CA) using a QX-
100 droplet generator (Bio-Rad, Hercules, CA) according to the manufacturer’s 
instructions. Samples were multiplexed with primers and probes specific for MeV N gene 
(5’ FAM; Table 2-1) and GAPDH (5’ HEX). The droplets were then transferred to a 96 
well reaction plate (Eppendorf, Hauppauge, NY) and heat-sealed with pierceable sealing 
foil sheets (Thermo Fisher Scientific, West Palm Beach, FL).  
PCR amplification was performed in the sealed 96 well plate using a GeneAmp 
9700 thermocycler (Applied Biosystems, Grand Island, NY) with the following cycling 
parameters: 10 minutes at 95°C, 40 cycles consisting of a 30 second denaturation at 94°C 
and a 60 second extension at 59°C, followed by 10 minutes at 98°C and a hold at 12°C. 
Immediately following PCR amplification, droplets were analyzed using a QX100 
droplet reader (Bio-Rad, Hercules, CA), in which droplets from each well are aspirated, 
streamed toward a detector and aligned for single-file two-color detection. All samples 
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and controls were run in quadruplets. Data are reported as [(copies of MeV N 
RNA)/(copies of GAPDH RNA)] x 5,000. 
 
Interferon bioassays 
 Serum samples collected from eight macaques (14Y, 17Y, 31Y, 46Y, 50Y, 46U, 
55U, and 67U) at days 0, 3, and 7 post-infection were analyzed for interferon production 
by bioassays. Vero cells were grown overnight in 96-well flat-bottom plates (Corning). 
Vero cells were then incubated with serum samples, recombinant IFNα (PBL Assay 
Science), or recombinant human IFNβ (Sigma) for 24 hours at 37°C, 5% CO2. IFNα and 
IFNβ controls were assessed in the range of 0.1-100,000 units/mL. The cells were then 
challenged with vesicular stomatitis virus expressing green fluorescent protein (VSV-
GFP, a gift from Sean Whelan at Harvard Medical School, Boston, Mass.) at an MOI of 
1.0 for 24 hours at 37°C, 5% CO2. As a negative control, Vero cells were incubated with 
media only and were not challenged with VSV-GFP. The positive control wells were 
incubated in media only and were challenged with VSV-GFP. Following infection, cells 
were trypsinized, washed with 1X PBS, and fixed with PBS + 1%FBS +1% 
formaldehyde for flow cytometry analysis to determine %GFP-positive cells. 
 
PCR Array 
 The expression of genes associated with the type I interferon response was 
profiled by Rhesus Macaque Type I Interferon RT2 Profiler™ PCR Array (SA 
Biosciences, Qiagen, Valencia, CA) which targets 84 different core genes involved in this 
pathway. Total RNA was extracted from PBMCs collected from macaque 31Y at days 0 
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and 7 post-infection and cDNA was synthesized using the RT2 First Strand kit (SA 
Biosciences, Qiagen, Valencia, CA). RT-PCR was performed using the RT2 SYBR Green 
qPCR Mastermix using Applied Biosystems Prism 7700 as instructed by the 
manufacturer (SA Biosciences, Qiagen, Valencia, CA). Data were analyzed by the RT2 
Profiler web-based software (SABiosciences) using the 2-ΔΔCT method. The expression 
levels for genes of interest were normalized to β2-microglobulin (B2M) and HPRT1.   
Based on a set of housekeeping genes on the PCR array, the software identifies the genes 
with the most stable expression. The CT values for those genes are then geometrically 
averaged and used for the ΔΔCT calculations. DAVID Bioinformatics Database 6.8 




Slow clearance of MeV RNA from PBMCs and nasal secretions  
We have previously shown that viral RNA persists in various tissues months after 
infectious virus is cleared during a primary MeV infection of young macaques (1-2 years 
of age) [23].  Because we were using an older cohort of macaques for this study, which 
offers the advantage of increased sample collection, we first wanted to examine whether 
age would impact the rate of viral clearance. Infectious virus in the blood was monitored 
by co-cultivation of PBMCs with Vero/hSLAM cells. All monkeys developed a viremia 
by day 7 and cleared infectious virus from PBMCs by day 18 (Figure 2-1). Additionally, 
all macaques developed a rash by 10 days post-infection (dpi) which was cleared by 14 
dpi (Figure 2-1).  
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MeV RNA was detected in respiratory secretions by 7 to 10 days after infection 
followed by continued shedding for 1-2 weeks (Table 2-2). MeV RNA in PBMCs 
gradually decreased after clearance of infectious virus and became undetectable 60 to 70 
days after infection (Figure 2-2). These data confirm that prolonged presence of viral 
RNA occurs in three phases and is characteristic of primary MeV infection (Figure 2-2) 
[23].  
 
MeV RNA detection in various subsets of immune cells  
 To determine the cell types in which MeV RNA could be detected, we used 
ddPCR (PBMCs) and qRT-PCR (LN) specific for the MeV nucleoprotein (N) gene 
(Figure 2-3). Cells isolated from PBMCs and inguinal lymph node biopsies were sorted 
into B cell, T cell, and monocyte populations using magnetic beads. In PBMCs, MeV 
RNA preferentially persisted in CD20+ B cells and was detectable before 60 dpi (Figure 
2-3a). Viral RNA levels in sorted PBMCs were below the limit of detection after 60 dpi 
consistent with viral RNA decay in total PBMCs (Figure 2-2). In the lymph node, MeV 
RNA was detectable only in CD20+ B cells at 71 dpi, but could be detected in CD3+ (T 
cells), CD20+, and CD14+ (macrophages) cells at 154 dpi (Figure 2-3b).  
 
Detection of type I IFN activity 
 Interferon bioassays were performed to determine the presence of type I IFN in 
serum samples collected at day 0, 3 and 7 post-infection. For this assay, the presence of 
type I IFN is assessed by the ability of cells incubated with the serum to block VSV 
infection, thereby resulting in a decrease in the percentage of GFP+ cells. There was no 
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detectable IFN activity at 3 or 7 days after infection (Figure 2-5b).  The sensitivity of the 
assay varied for IFNα and IFNβ (Figure 2-4). The detection limit for IFNα was in the 
range of 10-100 units/ml. However, titrations of IFNβ indicated that its activity could 
only be detected at higher quantities, between 104 and 105 units/ml (Figure 2-4). It is 
possible that IFNα/β is present in serum samples, but outside the limit of detection. 
Negative control wells were incubated with media only, were not challenged with VSV-
GFP and there were no GFP+ cells detected in these samples. The positive control wells 
were incubated in media only and challenged with VSV-GFP, these samples were not 
protected from infection and GFP+ cells were detected at frequencies greater than 90% 
(Figure 2-5a). 
 
Differential expression of type I IFN associated genes 
 To begin dissecting the underlying mechanism by which measles virus infection 
modulates type I IFN activity in PBMCs, we profiled the expression of genes associated 
with the type I IFN pathway before and at days after infecion using a PCR array. The 
results showed an increase in expression of genes associated with the RLR and TLR 
pathways, including TICAM1 (TRIF), TLR3, TLR7, IFNβ, IFNω, ISG15 and IL-6. 
However, other RLR and TLR pathway associated genes were down-regulated, including 
TLR8, TLR9, IFIH1 (MDA-5), IRF3, IRF5, and IFNα1. Moreover, there was down-
regulation of genes involved in the cytosolic DNA sensing pathway that promote the 
induction of type I IFN and proinflammatory cytokines, including ADAR1, IRF3, and 
CASP1.  
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 Lastly, some of the genes that were down-regulated by measles virus infection 
were associated with viral carcinogenesis or the development of human malignancies, 
these included SP100, IRF3, MAMU-B (MHCI), and STAT3. The expression of all 
genes differentially regulated during the acute phase of measles infection, prior to the 
onset of rash, and their functions are described in Table 2-3 and Table 2-4.  
 
2.5  DISCUSSION 
 
Measles virus RNA persistence 
MeV is able to efficiently replicate in cells of the immune system. In this study 
we have used experimental infection of rhesus macaques to characterize the prolonged 
presence of MeV RNA during primary infection. We have shown that MeV RNA can be 
detected in multiple sites months after infectious virus is cleared from the blood. While 
viral RNA was only detected in PBMCs until approximately 60 dpi, lymphoid tissue 
harbored viral RNA through six months post-infection. Additionally, we have shown that 
MeV RNA can be detected in various subsets of immune cells and from various tissues 
before and after infectious virus has been cleared. In all, we saw that MeV RNA 
preferentially persists in B cells in PBMCs and B cells and macrophages in the lymph 
node.  
  Previous studies have shown that N gene sequences from RNA recovered from 
five Zambian children 96-109 days after rash onset were identical to the circulating 
strain, with one child having N- and H- sequences at 118 days post-rash identical to that 
recovered from the same child during acute illness [108]. Therefore, it is likely that the 
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prolonged presence of MeV RNA in tissues after apparent recovery is attributable to slow 
clearance rather than the acquisition of escape mutations. It is possible however, that 
slow clearance of MeV RNA may be due to its ability to “hide” in certain subsets of 
immune cells. For example, Epstein-Barr virus (EBV) is able to establish latent infection 
within its host by persisting in an episomal form in B cells [115-117]. Studies in Zika 
virus-infected macaques demonstrated that viral RNA persists in lymphoid tissue through 
at least 35 dpi with preferential tropism for B cells and macrophages [118]. As a result, it 
has been hypothesized that ZIKV RNA persistence in peripheral tissues may be 
associated with post-recovery complications such as Guillain-Barre syndrome or other 
neurological sequelae [118]. 
Studies from macaques infected with an EGFP-expressing MeV demonstrated 
that memory T cells were preferentially infected in lymphoid tissues during the acute 
phase (9-11 dpi) of infection [20]. In the current study, we were able to detect MeV RNA 
not only in B cells, but also T cells and macrophages in lymphoid tissue at 154 days post-
infection (~5 months). Follicular helper T (Tfh) cells support viral replication and are 
possible latent reservoirs of HIV [119]. Tfh cells have been proposed as the cause of viral 
“blips” or reactivation in HIV patients who are receiving ART therapy [119]. While 
further studies need to be done to determine specific T cell subsets that may harbor MeV 
RNA it is possible that Tfh cells may serve as the primary T cell reservoir.  
In all, we saw that a primary wild-type measles infection resulted in the prolonged 
presence of viral RNA in the blood and lymph node. The consequences of RNA 
persistence vary depending on viral infection, tissue tropism and target cells. Further 
studies are needed to determine the exact consequences of the prolonged presence of 
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MeV RNA in peripheral tissues. The length of time required for clearance from lymphoid 
and other tissues is not known. However, the continued presence of MeV RNA in 
lymphoid tissue may explain the immune suppression associated with measles however, 
it is much more likely to aid in the maturation of virus specific immune responses and 
development of life-long protective immunity.  
 
Measles infection and type I interferon  
MeV has acquired several mechanisms to escape immune surveillance and inhibit 
attempts by the host immune system to suppress viral replication, clear virus and 
eliminate virus-infected cells. In this study, we have shown that wild-type MeV infection 
of rhesus macaques alters production of interferons (IFNs) and IFN-mediated signal 
transduction. Biologically active IFNα/β was not detectable in serum during the acute 
phase of MeV infection before the onset of rash. Therefore, it is likely that the lack of 
IFN induction contributes to the systemic spread and long incubation period of measles. 
Previous in vitro and in vivo studies suggest that in the absence of defective interfering 
RNAs, neither wild-type (WT) nor vaccine strains of MeV efficiently induce Type I or III 
IFN [35, 120]. Thus, the differential regulation of the IFN response is not important for 
attenuation.  
The exact mechanism(s) by which MeV inhibits the induction of the IFN response 
is still not fully understood. Some studies suggest that MeV is able to block type I IFN 
production by preventing activation of MDA-5 [37, 38]. In this study, gene expression 
analysis showed that MeV infection resulted in the down-regulation of MDA-5 and a 
gene involved in MDA-5 signaling, IRF3. The V protein of MeV has been shown to 
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prevent type I IFN induction by TLR7 and TLR9 by targeting IKKα [110, 111]. We 
observed an increase in TLR7 and a decrease in TLR8 and TLR9 mRNA expression. 
TLR7, 8 and 9 have extremely similar signaling pathways that involve IRF-5 and IRF-7 
mediated activation of type I IFNs [121]. We observed a down-regulation in IRF-5 but 
not IRF-7. It is likely that measles targets downstream effectors of endosomal TLR 
signaling to prevent type I IFN induction.  
Previous work in measles vaccinated and wild-type infected macaques did not 
observe significant increases in IFNα and IFNβ mRNA levels by qRT-PCR, when 
compared to controls [35].  We observed an increase in IFNβ and IFNω, but a decrease in 
IFNα mRNA levels. Despite these differences, levels of biologically active IFN could not 
be detected in serum by bioassay, suggesting inefficient protein production regardless of 
mRNA levels measured.  A role for MeV infection on IFNω expression has not been 
described. However, IFNω is a more potent inhibitor of HIV replication than IFNα2, and 
treatment of cells with IFNω resulted in a significant increase in ISG15 [122].  We also 
observed an increase in ISG15 expression, confirming previous findings that its 
expression may be induced by IFNω activation.   
Overall, our work confirmed that MeV infection inhibits the induction of type I 
IFN. Gene expression analysis suggests that MeV blocks type I IFN production through 
the down-regulation of MDA-5, TLR8, and TLR 9 pathways. This also suggests that any 
type I IFN that is produced is likely via the activation of the RIG-I or TLR 3 pathway. It 
will be important to repeat theses studies using samples from additional macaques to 
confirm our findings. However, our results begin to provide some additional insight into 
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the mechanisms underlying MeV regulation of type I IFN production and identify 









































Table 2-1. PCR primers and probe sequences used for the detection of the measles 
virus N gene  
 
Assay Target Primer and Sequence 
 
RT-PCR 
350 bp amplicon of 



























Figure 2-1. Clearance of infectious virus from blood. Macaques were infected 
intratracheally with the wild-type Bilthoven strain of MeV; viremia was measured by co-
cultivation of serially diluted PBMCs on Vero/hSLAM cells. Data are displayed as the 
log(TCID50)/106 PBMCs. Shaded area indicates period of rash. 
 
 






































Table 2-2. Detection of MeV RNA in nasal secretions. To monitor MeV shedding from 
the respiratory tract, nasal secretions were collected from both nostrils with sterile cotton 
swabs and immersed in PBS. Cells and fluid were separated via centrifugations. RNA 
was extracted from cell pellets. MeV N gene RNA was measured by RT-PCR and results 










 14Y 17Y 31Y 46Y 50Y 
Days post infection      
0 - - - - - 
7 - + - - + 
10 + + + + + 
14 + + + + + 
18 - + + - + 
21 - + - - + 




    
 
Figure 2-2. Slow clearance of viral RNA from PBMCs. MeV N gene RNA in PBMCs 
was measured by qRT-PCR. Samples were run in duplicate, means are graphed, with a 
standard of 101-108 copies of MeV RNA. MeV RNA load was normalized to the GAPDH 
control. Results are expressed as [(MeV N RNA copies)/(GAPDH RNA copies)]*5000. 
















































































































































































Figure 2-3. Detection of MeV RNA in immune cels. Mononuclear cels from blood 
(A) and inguinal lymph node (B) were isolated and sorted into CD3+, CD20+, and 
CD14+ subsets. MeV N gene RNA was measured and data are presented as [copies of 
































































Figure 2-4. Recombinant IFNα and IFNβ detection limits. IFN bioassays were 
performed and recombinant IFNα and IFNβ were assayed in the concentration range of 




Figure 2-5. Biologically active IFN in serum after MeV infection. Serum collected at 
days 0 (n=9), 3 (n=3), and 7 (n=9) post-infection were analyzed for type I IFN activity. 
Vero cells were incubated with media alone (A) or serum (B) and then infected with 
VSV-GFP. The %GFP+ cells were determined by flow cytometry. Graph shows the 
mean ±SEM.        
  
 
















Table 2-3. Genes over-expressed at day 7 versus day 0 post-infection 
Gene Symbol Gene Name Fold Change Primary Function 
TICAM1 Toll-like receptor adaptor 
molecule 1 
74.41 Adaptor protein containing a 
TIR-domain. TLR3 signaling 
IFNW1 Interferon omega-1 28.66 Binds IFNalpha/beta receptor. 
Type I IFN signaling. Antiviral 
activity 
TLR3 Toll-like receptor 3 25.90 Antiviral. Recognizes dsRNA. 
Induces activation of NFkB and 
production of type I IFN 
TLR7 Toll-like receptor 7 24.29 Recognizes ssRNA. Induces 
activation of NFkB, production 
of type I IFN and pro-
inflammatory cytokines. 
CRP C-reactive protein 23.47 Pentraxin-related. Acute phase 
response to infection and injury. 
CYP27B1 Cytochrome P450, family 27, 
subfamily B, polypeptide 1 
22.76 Vitamin D metabolism 
IFNB1 Interferon beta-1 18.81 Binds IFNalpha/beta receptor. 
Type I IFN signaling. Antiviral 
activity 
SLC1A2 Solute carrier family 1, member 2 12.00 Glutamate transporter 
HPX Hemopexin 9.49 Acute phase protein. Oxidative 
stress. 
MAL Mal, T-cell differentiation protein 7.19 T-cell signal transduction 
IL6 Interleukin 6  6.32 Inflammation and B cell 
maturation 
ISG15 Interferon-stimulated gene 15 4.84 Neutrophil chemotaxis. Cell-
cell signaling. Antiviral activity. 
IFI27 IFN alpha inducible protein 27 4.35 Promotes cell death. IFN-
induced apoptosis. 
CCL2 Chemokine (C-C motif) ligand 2 4.28 Monocyte and basophil 
chemotaxis.  
GBP3 Guanylate binding protein 3 4.04 Binds guanine nucleotides (i.e. 
GTP). Antiviral activity.  
CAV1 Caveolin 1 3.70 Cell-cycle progression 
CIITA Class II, major histocompatibility 
complex, transactivator 
3.01 Positive regulator of MHCII 
transcription. 








Table 2-4. Genes under-expressed at day 7 versus day 0 post-infection 
Gene Symbol Gene Name Fold Change Primary Function 
CASP1 Caspase-1 -14.43 Apoptosis. Proteolytic cleavage 
and activation of IL-1b 
PML Promyelocytic leukemia -12.60 Associated with PML- nuclear 
bodies, protein shuttling. Targets 
STATs, IRFs, & p53 to modulate 
cellular functions. 
VEGFA Vascular endothelial growth factor A -8.97 Proliferation and migration of 
vascular endothelial cells. 
TLR8 Toll-like receptor 8 -7.67 Recognizes ssRNA. NFkB 
activation.Type I IFN production. 
TLR9 Toll-like receptor 9 -6.90 Nucleotide sensing. NFkB 
activation. Production of pro-
inflammatory cytokines. 
IFIH1(MDA5) Interferon induced, helicaseC domain 1 -6.23 RNA helicase 
IFI35 Interferon-induced protein 35 -6.12 Type I IFN signaling 
CDC37 Cell division cycle 37 -4.74 Cell division cycle control 
IRF5 Interferon regulatory factor 5 -3.64 Induction of IFNα/β and 
inflammatory cytokines.  
RCBTB1 RCC1, BTB domain containing protein1 -3.64 Cell cycle regulation 
IRF1 Interferon regulatory factor 1 -3.63 Activator of IFNα/β transcription. 
Apoptosis. 
 
LOC719379 Protein kinase C zeta type-like -3.35 Cell proliferation and 
differentiation. 
MAMU-B MHC class I antigen -2.87 Primate specific MHCI antigen. 
IFNA2 Interferon alpha 2 -2.62 Regulation of IFNα signaling. 
Antiviral activity.  
SLC11A1 Solute carrier family 11, member 1 -2.56 Iron metabolism. 
ADAR Adenosine deaminase, RNA-specific -2.37 RNA editing by site-specific 
deamination of adenosines 
STAT3 Signal transducer and activator of 
transcription 3 
-2.24 Cell growth and apoptosis. TH17 
differentiation. 
BST2 Bone marrow stromal cell antigen 2 -2.19 Undetermined.  
SP100 SP100 nuclear antigen -2.14 Tumorigenesis. Cell growth and 
differentiation. 
IRF3 Interferon regulatory factor 3 -2.11 Transcription of IFNα/β and 
interferon-induced genes. 




Measles-specific humoral immunity: Maturation of antibody responses, 
germinal center formation and follicular helper T cells 
 
3.1 ABSTRACT 
Measles is one of the leading causes of vaccine-preventable childhood morbidity and 
mortality worldwide. Measle virus infection elicits a robust virus-specific cellular and 
humoral response that measles leads to the development of life-long protection. The 
humoral immune response to infection is generally considered most important when 
assessing vaccine efficacy and protection against measles. The goal of our study was to 
further understand the development of long-term humoral immunity after measles virus 
infection using a rhesus macaque model. We show that the antibody response is rapid, 
specific for various MeV proteins, and sustained for months after infection. However, the 
maturation of these responses is slow. MeV-specific antibody secreting cells were 
detected by 3-4 weeks post-infection and sustained through six-months post-infection. In 
addition, we observed continuous activation of lymph nodes along with Tfh-driven 
germinal center formation. This suggests that development of MeV-specific humoral 
responses for at least six-months post-infection may be driven by persistent antigen. 
Further studies on the development of the humoral response during MeV infection will 
help define its importance in controlling infection and understanding how long-term 




3.2  INTRODUCTION 
The host immune response to measles virus is essential for viral clearance, clinical 
recovery, and the establishment of life-long immunity. During the prodromal phase of 
MeV infection, early innate immune responses are important for controlling viral 
replication. Appearance of the rash is associated with the onset of the adaptive immune 
response. The adaptive immune response to measles consists of virus-specific humoral 
(antibody) and cellular responses. The humoral immune response to MeV infection is 
generally considered most important when assessing vaccine efficacy and protection 
against measles.  
Measles is typically accompanied by a rapid and robust antibody response. Antibody 
is first detectable at the onset of rash. MeV-specific IgM responses appear first, as early 
as 72 hours post-rash, and are maintained for approximately 28 days [123, 124]. The IgM 
antibody response serves as a marker of primary infection and is typically absent 
following reinfection or revaccination. IgG responses appear around 18 days post-
infection, increase in amount and avidity overtime, and are presumed to be lifelong. The 
most abundant and most rapidly produced antibodies are against the MeV N protein, and 
the absence of N-specific antibodies is one of the most accurate indicators of measles 
seronegativity [64, 125]. Antibodies to H and F proteins are less abundant, but are 
important for virus neutralization and protection against measles [43]. The isotypes of 
MeV-specific antibodies after immunization and natural infection have been well 
characterized. In general, IgG1, IgG3 and then IgG4 are the predominant isotypes 
produced [126].  
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One parameter useful in assessing the quality of an antibody response is antibody 
avidity. The avidity of an antibody is a measure of the overall strength of the antigen-
antibody complex.  The strength of antibody avidity increases over time as a result of 
somatic hypermutaion and affinity maturation of B cells within germinal centers of 
secondary lymphoid tissues. Measles virus infection or vaccination typically results in the 
eventual production of high avidity antibodies. Low-avidity antibodies are associated 
with a poor virus-specific humoral response and have been used to classify primary 
vaccine failures [127, 128].  
Follicular helper T (Tfh) cells are a subset of CD4+ T cells that provide help to B 
cells and play a key role in the germinal center reaction. Studies have shown that Tfh 
cells are essential for B cell proliferation, affinity maturation, and the generation of long-
lived memory and plasma B cells [129]. Unlike other helper T cell subsets, the 
differentiation of Tfh cells is a complex and tightly controlled process. A variety of 
cytokines and transcription factors have been found to aid in each stage of the Tfh 
development process. The transcription factor, BCL6, is a key master regulator of the 
differentiation process [129]. Tfh cells are phenotypically recognized by their expression 
of CXCR5, ICOS, Bcl-6, and PD-1 and functionally by their synthesis of high levels of 
IL-21 [129].  
Previous work has shown that MeV RNA can be detected in the lymph nodes 5-6 
months after infection (See Chapter 2). In this study, we characterized the evolution of 
the MeV-specific humoral immune response in rhesus macaques through six months 
post-infection. In addition, we investigated changes in lymphoid tissue architecture and 
the frequencies of Tfh cells in the blood. Our studies suggest that increased proliferation 
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within lymphoid tissue and circulating Tfh cells promote the prolonged induction and 
maturation of the MeV-specific humoral response.  
 
3.3 MATERIALS AND METHODS 
Animals  
Five male rhesus macaques (14Y, 17Y, 31Y, 46Y, and 50Y) infected 
intratracheally with the wild-type Bilthoven strain of MeV were studied for six months. 
Heparinized blood was collected from the femoral vein of each animal before infection 
and every 3-14 days after infection for six months. PBMCs and plasma were isolated by 
whole blood gradient centrifugation on Lympholyte®-Mammal (Cedarlane Labs).  
 
Plaque Reduction Neutralization (PRN) Assay 
Neutralizing antibody concentration in serum was measured using a plaque reduction 
neutralization assay. The Edmonston strain of MeV was mixed with serially diluted 
plasma (1:3 – 1:30000) and assayed for plaque formation on Vero cells using a 6-well 
plate format. Data reported are the reciprocal of the serum dilution at which the number 
of plaques is reduced by 50%.  
 
Enzyme Immunoassays 
EIAs were used to measure MeV-specific IgM and IgG in serum. 96-well Maxisorp 
plates (Nalgene Nunc International) were coated with lysate from MeV-infected Vero 
cells (1.16 µg/well; Advanced Biotechnologies). Plates were blocked with 2% non-fat dry 
milk for 2 hours at 37°C. Serially diluted plasma (1:50 – 1:25600) was added and 
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incubated at room temperature for 2 hours. Horseradish peroxidase (HRP)- conjugated 
goat anti-monkey IgM or IgG (Sigma) was used as a secondary antibody. Plates were 
developed using 3,3’,5,5’-Tetramethylbenzidine (TMB) as the substrate and reaction was 
stopped using 2M H2SO4. Plates were read at 450nm. The EIA titer was the highest 
dilution at which responses were twice the background. 
MeV protein-specific IgG responses were measured using H, F, or N antigens. 96-
well immunoplates were coated with lysates of L cells-expressing MeV-H or MeV-F, or 
with baculovirus-generated MeV-N [130, 131]. Antigens were diluted 1:1000 (MeV-H 
and –F) or 1:2000 (MeV-N). Blocking, serum dilution, IgG detection, and development 
were performed as above. 
To assess the avidity of MeV-specific antibody, EIAs were performed as described 
above and increasing concentrations (0.5M-3M) of ammonium thiocyanate (NH4SCN) 
was added for 15 minutes to disrupt the antigen-antibody interaction following plasma 
incubation. The avidity index was calculated as the concentration of NH4SCN required to 
remove 75% of bound antibody.   
 
Antibody Secreting Cells.  
To measure antibody-secreting cells in the peripheral blood and bone marrow, cells 
were isolated from blood and bone marrow aspirates using density gradient centrifugation 
with Lympholyte Mammal (Cedarlane Laboratories). Multiscreen HTS HA Opaque 
plates (Millipore) were coated with MeV-infected Vero cell lysate or with purified goat 
anti-monkey IgG, IgM, IgA (H&L) (Sigma) and incubated at 4°C overnight. After 
incubation, plates were washed twice with PBS and blocked with RPMI + 10% FBS at 
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37°C for 1 hour. Cells (0.5 x 106) were added to plates and incubated for 6 hours at 37°C, 
5% CO2. After incubation, plates were washed with PBS-T (1X PBS + 0.05% Tween-20) 
and bound immunoglobulin was detected with HRP-conjugated goat anti-monkey IgG 
(1:5000). Plates were developed with stable diaminobenzidine (DAB) solution 
(Invitrogen) and read on a Immunospot plate reader (Cellular Technology). Samples were 
run in duplicate and data are presented as antibody-secreting cells (ASCs) per 106 
PBMCs.  
 
Histology and Immunohistochemistry 
 Inguinal lymph node biopsies were taken at days 71, 72, 154, or 155 post-
infection. Tissues were embedded in paraffin, sectioned, and stained with hematoxylin 
and eosin. Deparaffinized lymph node sections were stained for Ki-67 (1:100; MM1, 
Novacastra) and using the Masson trichrome method for visualization of collagenous 
connective tissue fibers. To characterize immune cell distribution within the lymph node, 
tissue sections were deparaffinized and stained using anti-CD3 (1:400; A052, Dako)   and 
anti-CD20 (1:1000; L26, Dako). Histology and immunohistochemistry staining was 




Multicolor flow cytometry with intracellular cytokine staining was used to 
identify MeV-specific circulating follicular T helper cells (CD4+ CXCR5+). PBMCs 
were stimulated for 12 hours using pooled overlapping H or N peptides (1µg/ml), peptide 
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diluent dimethyl sulfoxide (DMSO) or staphylococcal enterotoxin B (SEB). Purified 
mouse anti-human CD28 (BD Biosciences, CD28.2) and anti-human CD49d (BD 
Biosciences, 9F10) were included with the peptides and DMSO. All stimulation mixes 
included protein transport inhibitors GolgiStop and GolgiPlug (BD Biosciences).  
Live/Dead® Fixable Violet Dead Cell Stain Kit (Invitrogen) was used to gate out 
dead cells. Prior to surface staining, cells were incubated with a human FcR block 
(eBioscience). All panels included anti-CD4 (Biolegend, OKT4) and anti-CD3 (BD 
Bioscience, SP34-2). A “dump gate” was used to gate out cells labeled with anti-human 
CD14 (BD Biosciences, M5E2) or anti-human CD20 (eBioscience, 2H7). Intracellular 
staining was done following fixation and permeabilization of cells. The Foxp3 Staining 
Buffer Set (eBioscience) was used. Intracellular staining was done to detect the 
transcription factor Bcl-6 (BD Biosciences, Q21-559) and cytokine IL-21 (eBiosciences). 
Samples were run on a BD FACS Canto II™ flow cytometer and analyzed using BD 
FACSDiva and FlowJo software. 
 
3.4 RESULTS 
Characterization of the MeV-specific humoral response 
Enzyme immunoassays were used to assess the dynamics of the MeV-specific 
antibody response. IgM was detectable by 14 dpi in all macaques, peaked at 21 dpi and 
was no longer detectable by 28 dpi (Figure 3-1a). Measles virus specific IgG antibodies 
appeared in circulation 3-4 weeks post-infection and were sustained at elevated levels 
through six-months post-infection, the last time point tested  (Figure 3-1b). To define the 
specificity of these antibodies we used enzyme immunoassays specific to measles 
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hemaglutinin (H), nucleocapsid (N), and fusion (F) proteins. All macaques developed 
antibodies specific to all three measles virus structural proteins. Antibody responses 
specific for the N protein were highest, followed by H and then F responses (Figure 3-
1d). Neutralizing antibodies, measured using a PRN assay, were detectable by 2-3 weeks 
post-infection and sustained through six months (Figure 3-1c). Because there is growing 
evidence that the quality of the antibody response is also important for protection we 
assessed antibody avidity.  Maturation of the antibody response was slow, as antibody 
avidity did not peak until 98-126 dpi (Figure 3-2).  
To further characterize the humoral response, we examined the induction of MeV-
specific antibody-secreting cells using a B-cell ELISpot assay. MeV-specific antibody-
secreting cells began to appear in PBMCs around 14 dpi and peaked later around 50 dpi 
(Figure 3-3b). In contrast, the maximal number of antibody-secreting cells was around 21 
days post-infection in the bone marrow (Figure 3-3d). Measles virus infection resulted in 
an increased production of total antibody-secreting cells in PBMCs at 14 dpi, while in the 
bone marrow an increase was not observed until 60 dpi (Figure 3-3a,c). In all, the 
production of antibody secreting cells is prolonged and maintained in the periphery and 
bone marrow through six months post-infection. 
 
Germinal center formation in lymph nodes  
 To determine whether the presence of viral RNA had any impact on lymphoid 
tissue pathology, immunohistochemistry was performed on tissues collected at 71-72 dpi 
and 154-155 dpi. Lymph nodes were reactive, with increased cellularity that included 
plasma cells and macrophages in addition to lymphocytes (Figure 3-4). Proliferation 
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within the tissues increased over time along with an increase in numbers of germinal 
centers (Figure 3-4 and 3-5c). At days 71-72 post-infection fewer than 10 germinal 
centers were identified within a lymph node section of each macaque. By 154-155 dpi, 
sections from three of the four macaques had almost double the number of germinal 
centers (Figure 3-5c).  The follicles in tissues collected at 154-155 dpi show abnormal 
germinal centers with marked hyalinization, this was observed in three out of four 
macaques (Figure 3-5). One macaque was excluded from analysis due to poor tissue 
quality. Lymph node sections were stained for CD3+ and CD20+ cells to characterize the 
distribution of T cells and B cells at late time points after infection (Figure 3-6). CD20+ 
cells were predominantly present around the periphery with fewer B cell areas in deep 
cortex (Figure 3-6a) while CD3+ cells were scattered within follicles (Figure 3-6b). 
 
CD4+ CXCR5+ cells increase in the blood late in infection 
Tfh cells in mice, humans and rhesus macaques express high levels of PD1 in 
addition to CXCR5, an essential chemokine receptor [132, 133]. While Tfh cells 
predominantly mediate their function in the lymph node, we sought to characterize these 
cells in the blood because it is a more easily accessible tissue and several lines of 
evidence suggest that circulating Tfh cell populations are generated from cells committed 
to the Tfh lineage and share functional properties with GC Tfh cells [134-136]. We first 
evaluated the expression of CXCR5 on CD4+ T cells specific for the MeV H- or N- 
protein (Figure 3-7a). We observed an increase in H-specific CD4+ CXCR5+ T cells 
from 0.65% ± 0.28 at 39 dpi to 2.61% ± 0.69 by 113 dpi. This same trend was observed 
with N-specific CD4+ CXCR5+ T cells (0.47% ± 0.09 to 3.97% ± 1.63). Next, we 
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examined the co-expression of CXCR5 and PD-1 on MeV-specific CD4+ T cells. There 
was an increase in H- and N-specific CD4+ CXCR5+ PD-1+ T cells over time (Figure 3-
7b and d).  
IL-21 is highly expressed by Tfh cells and is important for driving plasma cell 
differentiation [137]. We evaluated the production of IL-21 by CD4+ CXCR5+ T cells. 
Overall, we observed very little IL-21 production by H- or N- specific CD4+ CXCR5+ T 
cells. There was one monkey (14Y) that had increased IL-21 production at day 56 post-
infection. Also, we have not been able to detect IL-21 in plasma during measles.  
 
3.5 DISCUSSION 
In this study, we have shown that the antibody response to measles virus is rapid, 
however, the maturation of this response is slow. MeV-specific IgM was detectable by 14 
dpi, while IgG levels peaked at 21 dpi and were sustained through six months post-
infection. These antibodies were neutralizing and specific for the measles virus H, N, and 
F proteins. The quality of the antibody response gradually increased with peak antibody 
avidity occurring around 3-4 months post-infection. In addition, we observed the 
prolonged production of antibody secreting cells in the blood and bone marrow. 
Together, these data suggest that measles virus infection gradually induces the 
development of high quality long-lived plasma cells responsible for the long-term 
maintenance of measles-specific antibodies. Lastly, we observed an increase in 
proliferation and GC formation in lymphoid tissue, along with increased Tfh cells in 
circulation as the humoral immune response matured.    
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The process of affinity maturation arises through a balance between slow but 
steady elimination of lower affinity clones and variants leading to GC homogeneity and 
loss of clonal diversity [138]. There is increasing evidence that the avidity of antibodies 
induced by infection or immunization is important for protection. Vaccination with 
inactivated measles virus that leads to the rapid production of low avidity antibodies has 
been associated with primary vaccine failures, and the production of immune-complexes 
leading to atypical measles upon challenge [139-141].  Avidity maturation is dependent 
on Tfh cell help to B cells within germinal centers [129, 132, 142-144]. In our study we 
saw that measles infection resulted in a gradual increase in virus-specific Tfh cells in the 
blood coincident with an increase in antibody avidity and continued production of 
antibody secreting cells.  
GCs are transient structures that form within secondary lymphoid follicles upon 
antigen exposure. We have previously shown that viral RNA can be detected in various 
immune cells within the lymph node at 5-6 months post-infection (Chapter 2, Figure 2-3).  
In the current study, we have shown an increase in germinal center formation and 
proliferation in lymphoid tissue at six months compared to 2.5 months post-infection, 
indicating continued stimulation and antigen exposure. In addition, we observed 
increased hyalinization within germinal centers. Hyalinization refers to the process by 
which smooth muscle cells and collagen fibers appear to fuse and take on a 
homogeneous, acellular, “glassy” appearance [145]. This histological characteristic has 
been observed in rhadinovirus-infected macaques [146], in HHV-8 (KSHV) positive 
humans [147], and in chronic SIV and HIV infections [145, 148]. Hyalinization of 
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reactive germinal centers may be attributed to “burn-out” and is associated with marked 
lymphocyte depletion and an increase in plasma cells [145, 149]. 
Emerging evidence suggests additional roles for Tfh cells in virus clearance and 
as virus reservoirs.  Most viral infections are strong inducers of Th1 and Tfh responses, 
the differentiation of both being induced by IL-12 [129]. LCMV studies in mice suggest 
that viral persistence and prolonged TCR stimulation promotes the T cell differentiation 
from Th1 to Tfh cells [129, 150]. In addition, late production of IL-6 is essential for 
sustaining Tfh cells, promoting GC responses, and clearing infectious virus [129]. In 
HIV, Tfh cells increase in frequency, serve as viral reservoirs, and combination 
antiretroviral therapy reduces the proportion of Tfh cells carrying HIV DNA [119, 129]. 
Our data show that measles infection induces the expansion of Tfh cells and the 
frequency of these cells was highest later in infection. 
In all, a primary wild-type measles infection resulted in the prolonged induction 
and maturation of the humoral immune response; the dynamics of these responses are 
summarized in Figure 3-8. These observations correlated with increased proliferation 
within lymphoid tissue and circulating Tfh cells. Previous observations suggest that MeV 
RNA persistence in lymphoid tissue may aid in the maturation of virus specific humoral 
responses (Chapter 2; Figure 3-8). Further studies are needed to determine the 
distribution and concentration of Tfh cells in lymph nodes, and characterize B cell 
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Figure 3-1. Antibody responses in macaques after a primary wild-type MeV 
infection. Plasma levels of IgM (A) and IgG (B) antibodies from plasma were measured 
by an EIA using measles virus lysate as antigen.  Neutralizing antibody titers were 
measured using a PRN assay, in which serially diluted plasma collected at various time 
points was tested for its ability to neutralize the Edmonston strain of MeV in Vero cell  
(C). Antibodies to H, N and F MeV proteins were measured by EIA, data shown are 
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Figure 3-2. Avidity of MeV-specific antibodies. MeV-specific IgG avidity was assessed 
by determining the minimum concentration of NH4SCN needed to disrupt antigen-
antibody interactions. An avidity index (AI) was calculated. Calculation of an AI75 is 
shown in the graph for each monkey (A) and averaged responses (B), indicating the 













































A      B 
      
 
C      D 
  
 
Figure 3-3. Prolonged production of antibody-secreting cells during the course of 
infection. The humoral immune response was further characterized by examining the 
presence of total and MV-specific antibody-secreting cells (ASCs) in blood (A and B) or 
bone marrow (C and D) using a B-cell ELISpot assay. Plates were coated with measles 
virus lysate or Anti-monkey IgG, IgA, IgM and 5x10^6 cells were added to each well. 
All samples were run in duplicate and data are plotted are mean ASCs per 106 PBMCs. 
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Figure 3-4. Lymph node histopathology. Inguinal lymph node biopsies were colected 
at 71 dpi and 154 dpi. Tissues were fixed, embedded in parafin, sectioned, and stained 
for histological changes (H&E) and cel proliferation (Ki67). Tissues from al five 
macaques were colected at each time-point and analyzed, panels shown are from 
monkey 14Y (H&E) and 31Y (Ki67) and representative of the cohort. 
- R!
Figure 3-5 Characterization of germinal center formation and structure. Sequential 
sections of a 154 dpi inguinal lymph node biopsies stained for histological visualization 
of the basic architecture (A; H&E) and for the content of colagenous connective tissue 
fibers (B; Mason’sTrichrome stain). Germinal center formation was characterized at 71 
(n=4) and 154 dpi (n=3). Normal (black arow) and hyalinized (yelow arow) germinal 
centers for each section were counted for each macaque at each time point. Graphical 
representation for germinal center counts for each macaque is shown in panels C and D. 
- .!
Figure 3-6. Immunohistological profile of CD3- and CD20- expressing cels within 
lymph node sections. Sequential lymph node sections were stained with anti-CD20 (A) 
or anti-CD3 (B) to characterize localization of B cels and T cels, respectively, during 
late phases of measles virus infection in macaques. Images shown are from monkey 31Y 
at 154 dpi, were photographed at 20X objective, and are representative of al macaques 
analyzed. 
- - !
Figure 3-7. Characterization of Tfh cels in the blood. Frequency of H- and N-specific 
CD4+ CXCR5+ (A), CD4+ CXCR5+PD-1+ (B) and CD4+ CXCR5+IL-21+ T cels in 
the blood at day 39 (n=4), 56 (n= 4), and 113 (n=3) post-infection. (D) Representative 




Figure 3-8. A model summarizing the dynamics of the MeV-specific humoral 
response and viral RNA clearance. Antibody responses to measles virus infection are 
rapid, IgM (blue line) is detectable between 2-3 weeks post-infection. MeV IgG (green 
line) responses peak by 3 weeks post-infection, are sustained and specific for various 
viral proteins (H, N, and F).  However, maturation of the antibody is much slower, as 
high avidity antibodies are produced and peak between 4-5 months post-infection (red 
line). MeV-specific antibody responses are sustained via the prolonged induction of 
antibody secreting cells in the periphery and bone marrow (orange line). As MeV-
specific humoral responses develop viral RNA (dotted line) in PBMCs is eventually 
cleared  but, can still be detected in the lymph node (shaded areas) between 3 and 5 
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Chapter 4 
The Prolonged Evolution of T Cell Responses during  




Measles is an acute viral disease associated both with immune suppression and 
development of life-long immunity. Clearance of measles virus (MeV) involves rapid 
elimination of infectious virus during the rash followed by slow elimination of viral 
RNA. To characterize cellular immune responses during recovery, we analyzed the 
appearance, specificity and function of MeV-specific T cells between 2 and 24 weeks 
after respiratory challenge of rhesus macaques with wild type MeV. IFNγ- and IL-17-
producing cells specific for the hemagglutinin and nucleocapsid proteins appeared in 
circulation in multiple waves approximately 2-3, 8 and 18-24 weeks after infection. 
IFNγ-secreting cells were most abundant early and IL-17-secreting cells late. Both CD4+ 
and CD8+ T cells were sources of IFNγ and IL-17, and IL-17-producing cells expressed 
RORγt. Therefore, the cellular immune response evolves during MeV clearance to 
produce functionally distinct subsets of MeV-specific CD4+ and CD8+ T cells at different 








4.2 INTRODUCTION  
Measles is a highly contagious viral disease that remains an important cause of 
childhood morbidity and mortality [22] with most deaths due to secondary infections 
[151, 152]. Measles virus (MeV), the causative agent of measles, is transmitted by the 
respiratory route and has an incubation period of 10-14 days. From the respiratory tract, 
MeV spreads to local lymphatic tissue and then to multiple organs including the skin. The 
prodrome of fever, cough and conjunctivitis is followed by a maculopapular rash 
associated with development of the adaptive immune response and T cell infiltration into 
sites of MeV-infected skin cells [140]. Although infectious MeV is cleared soon after the 
appearance of the rash, MeV RNA persists in peripheral blood mononuclear cells 
(PBMCs), urine and nasopharyngeal secretions of both naturally infected children [107, 
108] and experimentally infected rhesus macaques [23] for several months.  
The host adaptive immune response is necessary for control and clearance of virus 
[153, 154] and both MeV-specific antibody and T cells contribute to gradual clearance of 
viral RNA from PBMCs [23]. Studies of both humans and monkeys suggest that CD8+ T 
cells are important for clearance of infectious virus during the rash. MeV-specific 
cytotoxic T lymphocytes appear in blood during natural infection [50] and experimentally 
infected macaques depleted of CD8+ T lymphocytes have viremias that are higher and of 
longer duration than immunologically intact monkeys [49].  
Although less well studied, CD4+ T lymphocytes are likely to be essential 
contributors to a successful immune response to MeV and establishment of life long 
immunity. Naïve CD4+ T cells develop into functionally distinct subsets defined by the 
conditions required for differentiation, transcription factor expression and cytokines 
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produced and important subtypes include Th1 cells producing interferon (IFN)-γ, Th2 
cells producing IL-4, Th17 cells producing IL-17 and Treg cells producing IL-10 [155]. 
Evaluation of cytokines in plasma of children with measles suggests that CD4+ T cells 
predominantly produce IFNγ  during the rash period followed by a later switch to IL-4, 
IL-10 and IL-13 secretion as antibody production matures suggesting early development 
of Th1 followed by Th2 and Treg CD4+ T cells [32, 57, 80]. The possible development of 
effector CD4+ T cells producing IL-17 during the response to MeV was suggested in a 
vaccine study, but has not been systematically evaluated [156].  
Because it is likely that the functional evolution of T cell subsets during the 
prolonged phase of MeV RNA clearance is important for eventual virus clearance, 
immune suppression and establishment of life-long protective immunity, we 
characterized cellular immune responses to MeV over a period of six months after 
infection of rhesus macaques with a wild type strain of MeV.  
 
4.3 MATERIALS AND METHODS 
Animals, infection and sample processing 
Five (14Y, 17Y, 31Y, 46Y and 50Y) 3-year-old male measles-naïve rhesus macaques 
(Macaca mulatta) were infected intratracheally with the Bilthoven strain of wild-type 
MeV, as previously described (See Chapter 2). Heparinized blood was collected from the 
femoral vein before infection and every 3-14 days after infection for six months. 
Beginning 10 days after infection, IDEXX Laboratories performed automated complete 




Enzyme-linked immunosorbent spot (ELISPOT) assays were used to identify PBMCs 
producing IFNγ and IL-17. Multiscreen HTS HA Opaque 96-well filtration plates 
(Millipore) were coated with mouse anti-human IFNγ antibody (BD Biosciences, 2 
µg/ml) or IL-17A antibody (eBioscience, 5 µg/ml) and blocked with RPMI/10% FBS. 
Cells were not stimulated or were stimulated with 1 µg/ml pooled hemagglutinin (H) or N 
overlapping peptides, 5.8 µg/ml MeV-infected Vero cell lysate (Advanced 
Biotechnologies) or 5 µg/ml concanavalin A (Con A). Freshly isolated PBMCs (105) 
were added to wells stimulated with Con A, H or N peptides and 5x105 PBMCs were 
added to non-stimulated and MeV lysate wells and incubated at 37oC/5%CO2 for 40-42 
hours. Biotinylated anti-human IFNγ (Mabtech, 7-B6-1; 1 µg/ml) or anti-human IL-17A 
(eBioscience, 64DEC17; 2 µg/ml) antibody was added for 2 hours. Plates were developed 
with avidin-horseradish peroxidase (BD Biosciences; 1:2000) and diaminobenzidine 
substrate. Plates were read and analyzed using an ImmunoSpot plate reader and 
ImmunoSpot 5.0 software (C.T.L.). Data are presented as spot-forming cells (SFCs)/106 
PBMCs. MeV-specific SFCs were determined by subtracting the spontaneous (no in vitro 
stimulation) SFCs from the MeV-stimulated SFCs at each time point. All assays were 
done in duplicate. 
 
Flow cytometry  
Multicolor flow cytometry with intracellular cytokine staining was used to identify CD4+ 
and CD8+ T cells expressing IFNγ, IL-17, and RORγt. PBMCs were stimulated for 12 
hours using pooled overlapping H or N peptides (1µg/ml), peptide diluent dimethyl 
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sulfoxide (DMSO) or staphylococcal enterotoxin B. Except where noted, all reagents 
were from BD Biosciences or eBioscience. Mouse anti-human CD28 (CD28.2) and anti-
human CD49d (9F10) were included with the peptides and DMSO. All stimulation mixes 
included GolgiStop and GolgiPlug.  
 
Live/Dead Fixable Violet Dead Cell Stain Kit (Invitrogen) was used to eliminate dead 
cells from the analysis. Prior to surface staining, cells were incubated with human FcR 
block. All panels included anti-CD3 antibody (SP34-2). For days 0-18 a “dump gate” was 
used to eliminate cells labeled with anti-human CD14 (M5E2), anti-human CD20 (2H7) 
or anti-human CD8 (SK1) and CD4+ cells were defined as CD14-CD20-CD3+CD8-, 
because the anti-CD4 antibody initially used (RPA-T4) stained monkey CD4+ T cells 
poorly. From day 28 onward, anti-human CD4 (Biolegend, OKT4) was used and CD4+ T 
cells were defined as CD14-CD20-CD3+CD4+. CD8+ cells were defined as CD14-CD20-
CD3+CD8+.  
 
Intracellular staining was done following fixation and permeabilization of cells. For days 
7-21, the Cytofix/Cytoperm Fixation and Permeabilization Kit and subsequently the 
Foxp3 Staining Buffer Set was used. Intracellular staining was done to detect the 
transcription factor RORγt (Q21-559) and the cytokines IFNγ and IL-17A. T cell 
functionality was determined by gating on CD3+CD4+ and CD3+CD8+ cells stained for 
expression of IFNγ, tumor necrosis factor alpha (TNFα), IL-2 or CD107a. Boolean gating 
was used to define all possible subsets. Percentages of cells that expressed one, two, three 
or four different functional markers were grouped and relative frequencies for each subset 
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within CD3+CD4+ and CD3+CD8+ T cell populations were calculated. Samples were run 
on a BD FACS Canto II flow cytometer and analyzed using BD FACSDiva, FlowJo and 
SPICE (version 5.1; NIAID, NIH) software.  
 
Statistics 
The significance of differences in IFNγ and IL-17 secreting cells was assessed by a one-
way ANOVA with repeated measures followed by Bonferroni’s multiple comparisons 
test (GraphPad Prism version 7.00). Means for each time point were compared to day 0 




Changes in circulating leukocytes  
The numbers of total white blood cells, lymphocytes, and neutrophils in circulation were 
depressed during the viremia (day 10) but levels rebounded after the virus was cleared 
and then generally they were within the normal range by four weeks after infection 
(Figure 4-1a). Both CD8+ and CD4+ T cell numbers were decreased from day 10-18 and 
then returned to baseline (Figure 4-1b). There was a transient increase in the CD4:CD8 
ratio as the viremia was cleared and then stabilized in the normal range (Figure 4-1c). 
 
ELISPOT analysis of IFNγ- and IL-17 secreting cells  
PBMCs secreting IFNγ (Figure 4-2a) and IL-17 (Figure 4-2d) as a result of in vivo 
activation were present at multiple times after infection with peaks at days 14-21, 52 and 
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126. In vitro MeV antigen stimulation resulted in a significant increase in MeV-
responding IFNγ-secreting cells at day 21 after infection coincident with the clearance of 
infectious virus and decline in viral RNA levels (Chapter 2 Fig 2-2; Figure 4-2b). In 
contrast, peak production of IL-17 occurred later on days 52 and 126 as viral RNA was 
being cleared (Chapter 2 Fig 2-2; Figure 4-2e).  
 
Both CD4+ and CD8+ T cells express IFN-γ during viral clearance and recovery  
To determine the cellular sources and MeV protein-specific responses of early and late 
IFNγ production during MeV infection, PBMCs were stimulated with overlapping H or N 
peptides and analyzed by multi-parameter flow cytometry. CD4+ and CD8+ cells specific 
for both H and N proteins were sources of IFNγ throughout the course of infection 
(Figure 4-3a,b). CD4+ T cells producing IFNγ in response to MeV peptide stimulation 
were most abundant in circulation at 10 and 84 days after infection (Figure 4-3a). 
Increased production of IFNγ by CD8+ T cells was observed in all macaques at 10 days 
post-infection (Figure 4-3b). A second wave of IFNγ-producing CD8+ T cells appeared 
from 84-140 days after infection in four of the five macaques (Figure 4-3b).  
  A series of studies have suggested that both the magnitude and quality of the T-
cell response is important to controlling virus infection [157-160]. Determination of the 
quality of T cell responses includes assessing the diversity or polyfunctionality of these 
cells by measuring the simultaneous production of multiple cytokines [157, 161].  The 
polyfunctionality of H- and N-specific CD4+ and CD8+ T cells were assessed by 
determining the ability of cells to simultaneously express IFNγ, IL-2, TNF-α (CD4+ and 
CD8+) and CD107a (CD8+ only). A large fraction of H-specifc CD4+ T cells were 
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polyfunctional (producing more than one cytokine) at 56 dpi (Figure 4-3c and 4-4a), 
while N-specific CD4+ T cells were more polyfunctional at 28 dpi (Figure 4-3c). In 
contrast, there was a large fraction of H- and N-specific polyfunctional CD8+ T cells at 
multiple time points after infection (Figure 4-3d and 4-5). Overall, CD4+ T cells were 
polyfunctional primarily at earlier time points (Figure 4-3c and 4-4) while CD8+ T cells 
were polyfunctional at both early and late phases of recovery (Figures 4-3d and 4-5). 
Thus, MeV infection induces prolonged multifunctional virus-specific T cell responses 
likely to be important not only for controlling and clearing infection but also for 
induction of long-term protective immunity. 
 
MeV-specific CD4+ and CD8+ T cells begin producing IL-17 after clearance of 
infectious virus  
To identify and further characterize the IL-17-producing cells induced during measles, 
surface and intracellular cytokine staining with multicolor flow cytometry was performed 
and a completed time-course analysis was completed on four of the five monkeys (Figure 
3-6). All monkeys developed MeV-specific Th17 (CD4+IL-17+) cells (Figure 4-6a). H-
specific Th17 cells increased from less than 0.01% (days 0 and 10) to 1.35-2.27% of the 
CD4+ T cell population at day 18, followed by intermittent increases above baseline 
throughout the follow-up period (Figure 4-6a). N-specific Th17 cells were more variable. 
On average, Th17 H- and N- specific responses were highest on days 18 and 168 after 
infection. 
MeV-specific Tc17 (CD8+IL-17+) cells were also induced after MeV infection 
with patterns of appearance in circulation similar to that of Th17 cells (Figure 4-6b). All 
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monkeys had an increase in H-specific Tc17 cells to 1.07-1.77% at day 18, whereas only 
monkey 31Y showed an increase in the frequency of N-specific Tc17 cells at day 18. 
Monkey 17Y had increases in both H- and N-specific Tc17 cells at day 56, while the 
other monkeys did not. All monkeys showed an increase in MeV-specific Tc17 cell 
frequencies at day 168 (Figure 4-6b). In summary, MeV H and N-specific CD4+ and 
CD8+ T cells producing IL-17 were detectable on day 18 when infectious virus was 
cleared and then again when viral RNA was no longer detectable in PBMCs.  
 
MeV-specific T cell expression of RORγt  
To better characterize the IL-17-producing cells, expression of the canonical IL-17 
transcription factor RORγt [162] was examined (Figure 4-6a-d). The triphasic appearance 
of MeV-specific Th17 cells was also seen for cells expressing RORγt. All monkeys 
exhibited an increase in H-specific (1.09%+0.23) and N-specific (2.50%+1.99) RORγt-
expressing CD4+ cells at day 18 (Figure 4-6a). Frequencies of RORγt-expressing cells in 
response to H and N peptide stimulation remained low at day 28 through 39 followed by 
variable increases at day 56 or day 84. After day 113, the frequencies of MeV-specific 
RORγt-expressing CD4+ T cells showed a steady increase to approximately 1-2% at day 
168 (Figure 4-6a).  
MeV-specific CD8+ T cells also expressed RORγt (Figure 4-6b). H and N-specific 
increases were detected at 18, 56 or 64, and 168 days after infection. All monkeys 
displayed an increase in H-specific RORγt-expressing CD8+ T cells at days 18 and 168 
(Figure 4-6b). MeV-specific CD8+ T cells expressing RORγt averaged approximately 4% 
of the total CD8+ T cells, with individual frequencies ranging from 0.5-10%. 
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In addition, we also characterized the simultaneous expression of IL-17 and 
RORγt.  To better visualize the dynamics of co-expression, histograms of CD4+IL-17+ 
cells and CD4+IL-17- cells (Figure 4-6c) and CD8+IL-17+ and CD8+IL-17- cells (Figure 
4-6d) were created and overlaid. Prior to infection, all populations had very low levels of 
RORγt expression, but by day 18, RORγt expression was detected (Figures 4-6c,d). At 
days 56 and 113, IL-17-positive cells had higher levels of RORγt than IL-17-negative 
cells in both stimulated and non-stimulated populations. However, at day 168, the ex vivo 
MeV-stimulation does not increase RORγt expression in IL-17-positive relative to IL-17-
negative cells.   
 
4.6 DISCUSSION 
Studies of measles in humans and macaques have suggested that T cell responses 
are important for recovery but the characteristics and time of appearance of MeV-specific 
T cells has received limited attention [49, 109]. In this study, we have monitored the 
evolution of T cell responses in MeV-infected rhesus macaques for a period of six 
months. Cells secreting IFNγ and IL-17 ex vivo and responsive to additional in vitro MeV 
stimulation appeared in circulation in multiple waves approximately 2-3, 8 and 18-24 
weeks after infection without a change in total lymphocyte counts. IFNγ-secreting cells 
entered the circulation within the first 2 weeks and were most abundant 2-3 weeks after 
infection coincident with clearance of infectious virus. Virus-specific CD4+ (Th1) and 
CD8+ (Tc1) T cells were sources of IFNγ early in infection, while CD8+ T cells were the 
predominant sources of IFN-γ later in infection. IL-17-secreting cells were most abundant 
later, were both CD4+ (Th17) and CD8+ (Tc17), expressed the transcription factor RORγt 
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and showed specificity for H and N MeV proteins. These data show an ongoing evolution 
of the virus-specific cellular immune response during MeV clearance and suggest that 
IFN-γ-production may be important for early viral control while IL-17 production may be 
more important late during clearance of viral RNA, maturation of the immune response 
and establishment of life-long protective immunity.   
Many IFNγ -producing CD4+ and CD8+ T cells were polyfunctional, secreting IL-
2 and TNF-α as well as IFN-γ. These data are consistent with previous observations of 
increases in levels of TNFα mRNA in PBMCs and of IFNγ, soluble IL-2 receptor, 
soluble CD8 and CD4 in plasma of children at the time of the measles rash [29, 55-57, 
80].  IFN-γ has potent antiviral activities through induction of antiviral proteins and 
IFNγ- producing CD8+ T cells are also likely to have cytotoxic activity, both of which 
contribute to clearance of many virus infections [163]. In vivo depletion of CD8+ T cells 
has demonstrated their importance for control of measles virus [49], simian 
immunodeficiency virus (SIV) [164] and hepatitis B virus [165] infections. Furthermore, 
CD4+ and CD8+ T cells can develop into memory T cells, which are more efficient 
producers of IFNγ upon restimulation and provide protection from reinfection. The 
second increase in IFNγ-producing CD8+ T cells in response to ex vivo stimulation 12-20 
weeks after infection may reflect this population. Although more studies are needed to 
characterize these cells, it is likely that the T cell increase early after infection is 
important for the clearance of infectious virus while the later response may indicate 
renewed appearance of effector cells or development of a memory response.  
A role for IL-17-producing cells in virus infection is less well characterized, but 
they have been implicated in impaired virus clearance and immunopathology as well as 
	 79	
improved outcome [166]. Th17 cells are induced from naïve CD4+ T cells in the presence 
of IL-6 plus some combination of TGFβ, IL-21 and IL-1β; a process that is inhibited by 
type I IFN [167] and suppresses Foxp3 expression necessary for Treg development. The 
innate response that occurs after MeV infection may facilitate the development of IL-17-
producing cells because IL-6 and IL-1β are increased early, but very little, if any, type I 
IFN is produced [29, 32, 35]. The time course for generation of IL-17-producing T cells 
has not been carefully assessed for most infections; however, a few studies suggest that 
peak production is often late.  For instance, in mice with keratitis due to herpes simplex 
virus infection, two waves of IL-17 mRNA (day 2 and day 21) are observed [168]. In 
children with respiratory syncytial virus-induced bronchiolitis, levels of IL-17 in 
nasopharyngeal secretions are higher in convalescence than during acute disease, in 
contrast to the other cytokines and chemokines measured [169]. Previous studies of 
macaques have shown increases in IL-17-producing cells at 10 and 35 days after MeV 
infection, but later times were not assessed [156]. In this study we have shown that IL-
17-secreting cells were not only produced early in infection (day 18), but also late during 
the recovery process (day 168) and that both CD4+ and CD8+ T cells are sources of IL-
17. While Th17 cells are polyfunctional, have multiple phenotypes and can play both 
detrimental and beneficial roles in disease pathogenesis, its role in measles is still 
unknown [167, 170, 171].  
Virus-specific Th17 cells have been detected as part of the CD4+ T cell response 
to viral infections of mice [168, 172-176], nonhuman primates [177-179] and humans 
[180-182]. Expression of IL-17 by recombinant vaccinia virus leads to increased levels of 
virus in tissues [183]. Numbers of NKT cells producing IL-17 correlate with failure to 
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control chronic SIV infection in macaques and higher levels of circulating Th17 cells 
correlate with higher viral loads and more severe liver disease in humans with chronic 
hepatitis B virus infection [184]. However, both improved clearance of influenza virus 
from the lung [185] and no effect on clearance of herpes simplex virus from the cornea 
[186] are also reported in response to IL-17-producing cells. The mechanism by which 
IL-17-producing cells may inhibit virus clearance is not clear.  
Many innate immune cells including innate lymphoid cells, NK cells, and NKT 
cells can produce IFNγ  and/or IL-17. It is likely that these cells may contribute to the 
small burst of IFNγ and IL-17 detected at seven days post-infection by ELISPOT assay. 
However, by 10 dpi all macaques had developed rash, a hallmark for the onset of the 
adaptive immune response during MeV infection [22]. Therefore, adaptive immune cells 
are likely the predominant producers of IFNγ and IL-17 after the first week of infection. 
These studies highlight the prolonged and complicated cellular immune responses 
generated by MeV infection. The immunologic processes driving the late development 
and repeated waves of IFNγ and IL-17-producing cells and the effects of these responses 






Figure 4-1. Changes in leukocyte counts after infection. Complete blood counts were 
used to measure the total numbers of circulating white blood cells (WBCs; dashed line), 
lymphocytes (gray line) and neutrophils (dotted line) (A). Normal ranges of cell counts 
for 3-4 year old rhesus macaques are: 7,700-13,000 WBCs/ml, 2,671-8,350 
lymphocytes/ml, and 2,671-5,147 neutrophils/ml. Percentages of lymphocytes that were 
CD4+ and CD8+ T cells were determined by flow cytometry (B) and the CD4:CD8 ratio 





Figure 4-2. ELISPOT detection of IFN-γ and IL-17-secreting cells. PBMCs from 
MeV infected macaques were left unstimulated (A,D) or were stimulated with H and N 
peptides (B-C) or MeV lysate (E-F) and cultured on plates coated with antibody to IFN-γ 
(A-C) or IL-17A (D-F) to determine numbers of spot-forming cells (SFCs) per 106 
PBMCs. To determine the numbers of cells producing IFN-γ (B) or IL-17 (E) in response 
to in vitro MeV stimulation, numbers of SFCs in unstimulated wells (A,D) were 
subtracted from the numbers of SFCs in MeV H and N or MeV lysate-stimulated wells. 
Total MeV-specific responses are also shown (C,F). Statistics used, one-way ANOVA 
with repeated measures followed by Bonferroni multiple comparisons test (n=5). 
*P<0.05; ***P<0.001; ****P<0.0001 
 
 






























































































































Figure 4-3. Assessment of the ability of MeV-specific T cells to produce effector 
cytokines over time. PBMCs were stimulated with pooled overlapping peptides from the 
MeV H or N proteins and IFN-γ-producing CD4+ T cells (A) and CD8+ T cells (B) were 
identified. The frequency of MeV specific IFNγ-producing cells was determined by 
subtracting the spontaneous response. The polyfunctionality of the MeV-specific T cell 
response was assessed by determining the ability of CD3+CD4+ T cells to simultaneously 
express IFNγ, TNFα, or IL-2 (C) and CD3+ CD8+ T cells for their ability to 
simultaneously express IFNγ, CD107a, TNFα, or IL2 (D). Pie charts show the functional 
composition of CD4+ and CD8+ T cells that simultaneously express one (gray), two 











Figure 4-4. Functional analysis of MeV-specific CD4+ T cells. PBMCs were 
stimulated with pooled H- and N- peptides. CD3+CD4+ T cells were assessed for the 
ability to simultaneously express IFNγ, TNFα, or IL-2 (A and B). Subsets of cells 
expressing each functional marker were analyzed by Boolean gating. The frequency of 































































































Figure 4-5. Functional analysis of MeV-specific CD8+ T cels. PBMCs were 
stimulated with pooled H- and N- peptides. CD3+CD8+ T cels were assessed for the 
ability to simultaneously express IFNγ, CD107a, TNFα, or IL-2 (A and B). Subsets of 
cels expressing each functional marker were analyzed by Boolean gating. The frequency 




Figure 4-6. IL-17 and RORγt expression of MeV-specific T cells. PBMCs were 
stimulated with DMSO diluent, pooled overlapping peptides from the MeV H or N 
proteins or staphylococcal enterotoxin B (SEB) and IL-17 and RORγt-producing CD4+ 
(A) and CD8+  (B) T cells were identified by intracellular cytokine staining and multicolor 
flow cytometry. CD4+IL-17+ (open) and CD4+IL-17- (gray) populations (C), and in 
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Chapter 6 
Measles virus-specific T cell responses in young adults 5 years after a 




 Measles is a highly contagious systemic viral infection. Two doses of measles, 
mumps, and rubella (MMR) vaccine are highly effective, however, secondary vaccine 
failures occur about 5% of the time. We assessed measles-specific T cell responses in 31 
young adults five years after receipt of a third dose of MMR (MMR3). Overall, there was 
a very minimal boost in MeV antigen-specific IFNγ or IL-17-producing T cells.  As most 
subjects were seropositive prior to MMR3 receipt, a routine third dose of MMR does not 













 Measles is a highly contagious, vaccine preventable disease. Despite the 
availability of a safe and effective vaccine, measles remains a major cause of morbidity 
and mortality globally among young children. Measles is typically a self-limiting disease 
characterized by fever, coryza, conjunctivitis, and rash. Recovery from infection results 
in life-long immunity. A number of live-attenuated measles vaccines are available 
(Chapter 1, Figure 1-5). In the U.S., the measles vaccine is administered to children as 
multivalent measles, mumps and rubella (MMR) vaccine.  
The current vaccination schedule is designed to provide optimal efficacy by 
administering the measles vaccine to infants following the decay of maternal antibody, 
but before the likelihood of exposure [93]. A live-attenuated vaccine against measles is 
administered to children in two doses. The WHO recommends administration of the first 
dose at nine months in measles endemic regions and 12-15 months in non-endemic 
regions. About 85% of children develop protective immunity to measles when vaccinated 
at 9 months, while 95% will develop protective immunity when vaccinated at 12 months 
[22]. Because measles is highly infectious with a reproductive number of 12-15, 
administering a second dose of the vaccine ensures that population immunity will reach 
sufficiently high levels (92-95%) to interrupt transmission.  
Two doses of the MMR vaccine are typically highly effective and sufficient to 
provide long-lasting immunity, however measles outbreaks have been reported among 
immunized individuals [139].  In addition, while most vaccinated individuals remain 
measles seropositive, antibody titers decrease 8-15 years post-vaccination [189, 190]. 
Waning immunity, and possibly secondary vaccine failures, can result in a shift in the age 
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distribution of measles from young children (< 5 years) to adolescents and young adults. 
In this study done in collaboration with the Centers for Disease Control (CDC), a third 
dose of MMR (MMR3) vaccine was administered to young adults more than 10 years 
after the second dose.  Antibody and T cell responses were assessed in a previous study at 
1 month and 1 year post-MMR3 vaccination. In this report, IFNγ and IL-17 ELISpots 
were used to assess MeV-specific T cell responses five years post-MMR3 vaccination.  
 
6.3 MATERIALS AND METHODS 
Study Subjects 
Participants in this study were young adults age 18-24 years old who had previously 
received the MMR vaccine at Marshfield Clinic in Marshfield, Wisconsin.  These 
subjects were part of the “MMR2 study” that examined immune responses in 612 
children after administration of a second dose of MMR vaccine. In the MMR2 study, 
cellular immune responses were assessed in a subgroup of 60 children. As part of the 
current “MMR3 study”, subjects from the MMR2 study (n=35) along with subjects not 
part of this study but of a similar age (n=15) received a third dose of MMR vaccine. 
Previous studies assessed their immune responses both at 1 month and 1 year after receipt 
of their third dose of MMR [191]. For this study, we have measured the cellular 
responses of 31 subjects five years after their 3rd dose of MMR. 
 
Cells 
Cryo-preserved PBMCs were thawed and washed twice with RPMI media supplemented 
with 10% human serum type AB. Cells were then cultured overnight at 37°C, 5% CO2 in 
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RPMI media supplemented with 4% human serum type AB, 1% penicillin/streptomycin, 




Enzyme-linked immunosorbent spot (ELISPOT) assays were used to identify 
IFNγ and IL-17 producing cells. Multiscreen HTS HA Opaque 96-well filtration plates 
(Millipore) were coated with mouse anti-human IFNγ antibody (BD Biosciences, 2 
µg/ml) or IL-17A antibody (eBioscience, 5 µg/ml) and blocked with RPMI medium 
(RPMI + 4% human serum AB + 1% penicillin/streptomycin, and 1% 200 mM L-
glutamine 1%). Cells were not stimulated or were stimulated with 1 µg/ml pooled 
hemagglutinin (H) or (N) overlapping peptides, or 5 µg/ml concanavalin A. PBMCs (105) 
were added to wells stimulated with ConA, and 5x105 PBMCs were added to H- or N- 
stimulated and unstimulated wells. Cells were incubated at 37oC/5%CO2 for 40-42 hours. 
Biotinylated anti-human IFNγ antibody (Mabtech, 7-B6-1; 1 µg/ml) or anti-human IL-
17A antibody (eBioscience, 64DEC17; 2 µg/ml) was added for 2 hours. Plates were 
developed with avidin-horseradish peroxidase (BD Biosciences; 1:5000) and 
diaminobenzidine substrate (Invitrogen). Plates were read and analyzed using an 
ImmunoSpot plate reader and ImmunoSpot 5.0 software (C.T.L.). Data are presented as 
spot-forming cells (SFCs)/106 PBMCs. MeV-specific SFCs were determined by 
subtracting the spontaneous (no in vitro stimulation) SFCs from the MeV-stimulated 




Measles virus-specific T-cell responses of 31 subjects 5 years after MMR3 receipt 
were assessed by IFNγ ELISpot (Fig 6-1a). ConA stimulation of PBMCs from all 
subjects were positive, ensuring that a lack of response was not due to the inability of 
cells to be stimulated. Virus-specific responses were determined by stimulating cells with 
pooled overlapping peptides specific for the measles hemagglutinin (H) or nucleocapsid 
(N) protein. The mean number of IFNγ spot forming cells (SFCs) per million PBMCs 
were 110.2± 391.7 with H-specific and 8.2± 12.9 with N-specific peptide stimulation 
(Figure 6-1a;Table 6-1). Due to large outliers, median values were also determined. The 
median SFC was 0 for the non-specific (unstimulated) response. The medians for peptide 
stimulation responses were 2 SFCs for H-specific and 4 SFCs for N-specific responses 
(Table 6-1).  In general, most subjects had a much higher H-specific versus N-specific 
response while 10 of 31 (32.3%) subjects had no detectable virus-specific response 
(Figure 6-1). The majority of responding subjects had H- and N-specific responses above 
the threshold, based on background responses, of 20 SFCs per million PBMCs (Figure 6-
2; Table 6-2) 
 PBMCs were available from a subset of 16 subjects to assess IL-17 producing 
cells 5 years post-MMR3 vaccination. Most subjects exhibited no IL-17 related cellular 
immune responses (Figure 6-1b). Two of the 16 subjects had an H-specific response and 
two of 14 subjects responded to N peptide stimulation. Mean MeV-specific responses 
were 0.95 ± 2.47 for H-specific responses and 0.50 ± 0.69 SFCs per million PBMCs for 
N-specific (Table 6-1). All responses were below the threshold of 20 SFCs per million 
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 Cell-mediated immunity (CMI) of 31 subjects five years after receipt of a third 
dose of MMR was assessed using IFNγ ELISpot assays. Among the subjects tested, 21 
(67.7%) exhibited MeV antigen-specific IFNγ production by T cells. These data suggest 
memory T cell responses have been maintained and can be detected five years post-
vaccination in most subjects. Memory T cell responses have been reported to increase 
initially after measles vaccination and can still be detected seven years post-vaccination 
in children and adults [192]. Previous studies involving a subset of subjects from this 
MMR3 cohort assessed CMI responses at baseline (pre-vaccination), at 1-month, and 1-
year post-vaccination. These studies found that while T cell responses were detected after 
a third dose of vaccination, they were not significantly increased when compared to 
baseline levels [191]. In a previous study of macaques vaccinated with a dry powder 
formulation of live-attenuated measles virus, only small increases in T cell responses 
were reported after challenge [193]. 
 The role of Th17 cells in primary immune responses against many infections have 
been well documented, however recent advances suggest that Th17 cells may play a 
critical role in vaccine-induced immunity. There is growing evidence that long-lived, 
robust memory Th17 cell populations exist, exhibit some polyfunctionality, and are 
induced during vaccination to various pathogens [194]. IL-17 appears to be a major 
modulator in the generation of protective immunity in response to whole cell pertussis 
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[195] and rotavirus (VP-6) vaccination [196]. The role of Th17 cells in natural or 
vaccine-induced measles immunity is still unknown. However, we have shown that MeV-
specific Th17 cells could not be detected in most subjects 5 years post-MMR3 
vaccination. It is possible that Th17 cells may be transiently induced immediately after 
vaccination and are not as long-lived as IFNγ-producing T cells. This suggests that Th17 
cells may play a minimal role in protective immunity to measles.  
 In summary, we were able to detect measles antigen-specific IFNγ producing T 
cells in the majority of subjects five years after receipt of the third dose of MMR. In 
contrast, MeV-specific IL-17 producing T cell responses were all below a threshold of 20 
S.F.C. per 106 PBMCs. Therefore, IFNγ-producing memory T cells may play a role in 
protective immunity to measles while Th17 memory cells may not. Additionally, while 
measles-specific cell mediated responses can be detected years after receipt of a third 
dose of MMR, further studies are necessary to support the need for administration of a 




















IFNγ     
Mean S.F.C. ±SD (n) 4.11 ± 8.00 (31) 110.20 ± 391.70 (31) 8.34 ± 12.86 (30) 
Median S.F.C. 0 2.00 4.00 
IL-17     
Mean S.F.C. ±SD (n) 0 (16) 0.95 ± 2.47 (16) 0.50 ± 0.69 (14) 
Median S.F.C. 0 0.1 0.1 
 
 
Table 6-1. Summary of measles-specific IFN-γ and IL-17 producing cells 5-years 
post third dose of MMR. PBMCs were isolated and stimulated with either media alone 
(unstimulated), pooled H peptides, or N peptides. The table shows mean and median 










Figure 6-1. Detection of IFN-γ and IL-17-secreting cels. PBMCs from subjects were 
left unstimulated or were stimulated with H and N peptides or Concanavalin A and 
cultured on plates coated with antibody to IFNγ (A) or IL-17A (B) to determine numbers 
of spot-forming cels (SFCs) per 106 PBMCs. To determine the numbers of cels 
producing IFNγ (A) or IL-17 (B) in response to in vitro MeV stimulation, numbers of 










































































Figure 6-2. Frequency of MeV-specific T cell responses among subjects.  The 
histogram shows the percentage of subjects that had H- or N-specific IFNγ S.F.C. per 106 



































IFN-γ    
< 20 S.F.C.  24 (77.4%) 28 (90.3%) 
≥ 20 S.F.C. 7 (22.5%) 3 (9.7%) 
IL-17    
< 20 S.F.C.  16 (100%) 14 (100%) 
≥ 20 S.F.C. 0 (0%) 0 (0%) 
 
Table 6-2. Summary of the frequency of MeV-specific IFNγ and IL17 responses 
among subjects. The table shows the number and percentage of subjects that had H- or 















General Discussion and Conclusion 
 
The immune response to measles virus infection is a complex cascade of innate, 
cellular, and humoral immune responses leading to eventual recovery and the 
establishment of lifelong immunity. Although measles is a well-known disease that has 
been extensively studied, many aspects of disease pathogenesis remain unclear. 
Experimental infections of non-human primates have helped to improve our overall 
understanding of the pathogenesis of measles, and have been especially vital in studying 
early events before the onset of rash and late events after apparent recovery.  
We have utilized a rhesus macaque model to assess viral RNA clearance, innate 
immunity and the evolution of the adaptive immune response during a primary wild-type 
measles virus infection. Collectively, this work was able to model the dynamics of 
various aspects of the host immune response to measles over an extended period of time, 
and develop our understanding on the role of MeV RNA persistence during infection. We 
found that viral RNA was cleared from the blood by two to three months post-infection, 
but still detectable in lymphoid tissue through five months post-infection. In addition, we 
demonstrated that viral RNA preferentially persisted in B cells in the periphery and in 
both macrophages and B cells in lymphoid tissue. This work offers new insights into 
various aspect of measles pathogenesis including prolonged immune suppression, long-
lived immunity, and late development of progressive neurologic disease. Next, we 
evaluated the ability of MeV to regulate type I IFN responses. The data obtained here 
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suggest that while type I IFN is not induced during the innate response to measles, other 
innate responses are likely to play a role in activating the adaptive immune response. 
  Moving on to characterization of the dynamics of the adaptive immune response, 
our evaluation of the humoral response has shown that WT measles virus infection results 
in the prolonged induction and maturation of antibody responses. This work has aided in 
our understanding of the mechanism behind the development of long-term immunity 
associated with measles. We analyzed the appearance and function of MeV-specific T 
cells over six months. These studies showed the prolonged and ongoing evolution of the 
cellular immune response generated by MeV infection, and suggest that polyfunctional T 
cells are important for viral clearance and recovery. Lastly, we evaluated cellular 
immunity in a cohort of young adults after receipt of a third dose of MMR. This study 
was done in collaboration with the CDC and these results from this data will aid in our 
understanding of measles vaccine long-term immunity.  
 
MeV RNA persistence: Mechanism and Consequences 
 Our work demonstrates that MeV RNA persists in several locations for many 
weeks to months after the clearance of infectious virus. Measles-associated immune 
suppression has long been described, but the underlying mechanism remains unclear. The 
continued presence of MeV RNA in multiple tissues may contribute to immune 
suppression. Many viruses that cause immune suppression can infect cells of the immune 
system [154]. MeV can infect T cells, B cells, and monocytes and we have observed the 
prolonged presence of MeV in each of these immune cells.  
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 MeV RNA persistence may play an important role in sustaining and driving 
antibody responses, leading to the establishment of life-long immunity. In the case study 
presented in Chapter 5, we observed that the lack of a robust MeV-specific antibody 
response correlated with undetectable levels of MeV RNA in multiple tissues. We have 
also shown that sustained levels of MeV RNA in lymphoid tissue are coincident with 
ongoing proliferation and Tfh cell expansion.  
 Viral RNA persistence has been described for animal models of acute viral 
encephalitis [197], hepatitis, and arthritis [198].  Rhinovirus and enterovirus RNA 
persistence has also been described in children for up to five weeks after the acute phase 
of infection [199]. While the consequences of viral RNA persistence for some infections 
have implications in pathogenesis, the significance of persistence for many infections, 
including measles, is still not clear. Our work has begun to provide some insight into the 
importance of the prolonged presence of MeV RNA. 
 The mechanism by which MeV RNA is able to persist is still unclear. It is 
possible that persistence may occur via low-grade replication. The nature of the RNA 
detected at later time points is still undetermined as our current assay is targeted towards 
detection of the MeV nucleocapsid (N) gene and does not distinguish between plus- and 
minus-strand RNA. Therefore, it is unknown whether we are detecting full length RNA 
or the ratio of genomic (-) versus messenger (+) RNA that is being recovered. Studies in 
mice revealed that coxsackievirus plus- and minus- strand viral RNAs were present at 
near equivalent amounts and persisted via the production of a stable double-stranded 
conformation [200].  In future studies, it will be important to develop a qRT-PCR assay 
with primers and probes specific for other measles virus genes and strand polarity. If we 
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detect viral mRNA after the clearance of infectious virus, this would indicate active 
transcription, and continued translation of protein to stimulate immune cells, occurring 
during the recovery phase. In addition, this will begin to provide some insight into the 
molecular mechanism of measles RNA persistence.  
 The ability to avoid recognition by the immune system is likely to be another 
critical factor in viral persistence. We observed that MeV RNA preferentially persisted in 
specific subsets of immune cells, specifically B cells and monocytes. MeV RNA could 
also be detected in T cells in lymphoid tissue although at much lower quantities.  This 
suggests that viral RNA may be able to persist by “hiding” out in specific immune cell 
types. Viruses such as cytomegalovirus (CMV) and HIV have been shown to persist in 
monocytes and macrophages [201]. It will also be interesting to determine whether viral 
RNA is being detected in specific memory cell populations. Thus, further phenotypic 
characterization of lymphocyte populations that harbor MeV RNA for extended periods 
of time is needed to give us better insight into the role and mechanism of RNA 
persistence.  
 
Innate Immune Response to Measles 
 The types of innate immune responses induced during measles have not been 
completely defined. We have shown that in vivo infection with wild-type MeV inhibits 
the induction of type I IFN. This phenomenon is not affected by virus attenuation as type 
I IFN induction was not observed in monkeys infected with vaccine MeV [35]. The MeV 
C and V proteins are primarily responsible for the regulation of type I IFNs during 
measles infection and mutations in the V protein inhibit its ability to block IFN 
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production [202]. The V proteins of most paramyxoviruses can inhibit IFN induction by 
directly targeting MDA-5. This supports the observation that the antagonistic function of 
type I IFN by the V protein requires interaction of the conserved, C-terminus with MDA-
5 [203]. 
 Another mechanism that MeV may use to circumvent the IFN response is by 
limiting the production of PAMPs. The V protein of MeV could function to control virus 
transcription and regulation by inhibiting the activity of the phosphoprotein (P) or the 
large protein (L) as described for other paramyxoviruses [36]. The MeV C protein also 
negatively regulates viral RNA synthesis by inhibiting the RNA polymerase [8]. While it 
is clear that MeV has evolved strategies to inhibit type I IFN induction, the viral 
PAMP(s) involved in activating the innate immune response is still unknown. The tightly 
controlled regulation of type I IFN during measles virus infection suggests that other 
innate immune responses are important for controlling replication and activation of the 
adaptive immune response.  
  
Adaptive Immune Response to Wild-type Measles Virus 
 Many aspects of the development of adaptive immune responses shortly after 
MeV infection have been well characterized. Recovery from infection with wild-type 
MeV results in prolonged protective immunity, however the mechanism involved in the 
induction of this robust immune response is not fully understood.  The development of an 
animal model for measles, specifically the macaque model, has allowed for a more 
longitudinal analysis of the dynamics of the adaptive immune response during infection. 
Previous studies in rhesus macaques have only analyzed the development of MeV-
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specific immune responses through approximately 3 months post-infection [23]. In our 
current study, we have described both cellular and humoral responses to measles 
infection through six-months post-infection. Understanding how long-lived protective 
immunity is established can have major implications for understanding other viral 
diseases and vaccine development.  
 Antibodies to measles virus are important for protection, and virus-specific 
neutralizing antibody levels correlate with protection from disease [64]. B cells undergo 
somatic hypermutation in germinal centers, which allows for the selection of cells 
producing high affinity antibodies for a specific foreign antigen. Our data showed a 
progressive increase in antibody avidity along with an increase in cellular proliferation in 
lymphoid tissue, which suggests prolonged germinal center Tfh cell activity and B cell 
selection through six months post-infection. It will be important in future studies to 
characterize the evolution of B cell responses in the periphery and Tfh cell responses in 
lymph node to better understand the development of MeV-specific humoral immunity. 
We also observed that deficits in antibody responses did not affect virus clearance or 
disease pathogenesis. This supports an important role for cellular responses in viral 
immunity, and suggests that both antibody and T cell responses should be studied when 
assessing vaccine efficacy.  
 Our study has shown that measles infection induces prolonged multi-phasic virus-
specific T cell responses. During the first two weeks following infection T cells are 
predominantly producing IFNγ followed by a shift to IL-17 production around two to 
three months post-infection. This shift to IL-17 production during measles convalescence 
is coincident with the production of Th2-associated cytokines, previously described [80], 
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and implies a functional change in the antigen presenting cells stimulating differentiation 
of naïve T cells. These changes in the cytokine profile may, in part, account for the 
susceptibility of individuals to secondary infections following MV infection, and may 
also promote B cell maturation and prolonged production of antibody secreting cells. We 
also observed late production (~5-6 months p.i.) of IFNγ and IL-17 by T cells which may 
represent memory populations, especially because there is growing evidence of the 
existence of Th17 memory cells in addition to effector and central memory populations 
[194]. Further phenotypic analysis of T cell populations by FACS analysis would be 
needed to gain a more detailed explanation of the cellular sources of late IFNγ and IL-17 
production.  
The exact role of Th17 responses during MeV infection is still unknown and this 
is one of the first studies to explore the dynamics of Th17 responses through six-months 
post-infection. Tregs prevent excessive effector T cell activation [204] and can modulate 
the proinflammatory nature of Th17 cells. In the current study, we did not study the 
dynamics of Tregs, which also may play an important role in recovery from measles virus 
infection. In mice, IL-17 can both increase Tregs [175, 205] and inhibit T cell 
cytotoxicity. In RSV, an imbalanced Th17/Treg response can result in exacerbation of 
lung inflammation and more severe disease [204]. During the response to MeV, Foxp3 
expression in PBMCs is low 7-14 days after infection, then increases and is sustained 
once infectious virus is cleared [23]. Therefore, it is possible that the balance between 
generation of Tregs and Th17 cells after the acute phase of infection promotes recovery 
and affects the process of MeV RNA clearance.  
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Adaptive Immune Response to Measles Vaccine 
 The most effective means of preventing measles is through immunization with a 
live-attenuated virus. Measles vaccines induce both humoral and cellular immune 
responses, and the duration of vaccine-induced immunity is at least several decades if not 
longer. While some correlates of protection from measles have been identified, the 
mechanism behind vaccine-induced protective immunity is still poorly understood. 
Furthermore, the durability of protection has been questioned due to reports of measles 
outbreaks in vaccinated populations [206, 207]. 
We participated in a study assessing the adaptive immune response in adolescents 
five years after receipt of a third dose of MMR.  We observed MeV-specific IFNγ-
producing T cell responses that were predominantly specific for the H protein. Previous 
studies have shown that vaccination with alphavirus replicon particles expressing H 
(VEE/SIN-H) induced protective immunity [208]. This vaccine induced a Th1 cytokine 
bias following challenge, in contrast to the Th2 cytokine bias induced by a non-protective 
vaccine [208]. Thus, H-specific Th1 responses are likely an important contributor in 
MeV-induced vaccine immunity. Collectively these data offer new approaches to vaccine 
strategies, suggest T cell responses are important for vaccine immunity, and provide 
additional parameters for assessing vaccine efficacy.  
Previous reports from the cohort included in our study observed no increase in T-
cell responses at neither 1-month nor 1-year post-MMR3 receipt compared to baseline 
[191]. These data suggest that a third dose of vaccine may not effectively boost measles 
immunity. However, various studies have reported a waning in measles-specific antibody 
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titers and T cell responses [189, 209]. Therefore, alternative strategies should be 
considered to solve the problem of waning immunity.  
 
The overall goal of our study was to characterize the dynamics of MeV clearance 
and several aspects of the immune response to wild-type measles. We hypothesized that a 
primary wild-type measles infection would be characterized by a failure of the innate 
immune response to induce IFN, but would result in viral RNA persistence 
predominantly in B cells from PBMCs of blood and lymphoid tissue. In general, we 
expected the MeV-specific humoral response to be rapid, stable and prolonged, while, the 
virus-specific cellular immune response would be more dynamic exhibiting peak 
functionality at earlier time points (2-8 weeks) post-infection.   
We have demonstrated that the innate immune response to measles does not 
involve the induction of type I interferon. However, primary infection results in the 
prolonged presence of viral RNA in multiple tissues and various immune cell types. Viral 
RNA persistence was especially prolonged in lymphoid tissue and predominantly in 
antigen presenting cells. In correlation with this, we saw prolonged measles-specific 
humoral and cellular immune responses through six-months post-infection.  
We speculate that viral RNA may be able to persist by existing in a more stable  
or higher order conformation. As a result, the prolonged presence of viral RNA, and 
possibly protein, in lymphoid tissue after WT MeV infection leads to continuous 
stimulation of antibody and T cell responses that result in life-long immunity. In addition, 
we observed the ongoing evolution of the virus specific cellular immune responses during 
MeV RNA clearance, which suggests that multifunctional T cells may regulate immune-
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mediated clearance. A better understanding of the evolution of ASC and GC responses in 
persistently infected lymph nodes, will help to inform the induction of long-lived plasma 
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